Antimicrobial immune regulation
By using heterologous microbial pathogen-specific antigen preparations to modulate the host's immune system, the problem of insufficient immune response to heterologous microbial infection in existing technologies has been solved, especially in immunosuppressed or immunocompromised patients, achieving effective protective immunity and infection prevention and control.
Patent Information
- Application Number
- CN202110547299.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2014-05-02
- Filing Date
- 2015-05-01
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In existing technologies, antimicrobial vaccines can usually only elicit specific adaptive responses, making it difficult to effectively combat infections from foreign microorganisms. Furthermore, immunosuppressed or immunocompromised patients are unlikely to acquire protective immunity through conventional vaccines.
Antigen formulations containing specific antigenic determinants of heterologous microbial pathogens are administered via subcutaneous or intradermal application in continuous doses to modulate the host's immune system to treat or prevent microbial infections, especially in immunosuppressed or immunocompromised patients.
It can stimulate an effective immune response in heterologous microbial infections, provide protective immunity, enhance the anti-infection ability of immunosuppressed or immunocompromised patients, and reduce the risk of infection recurrence.
Smart Images

Figure CN113855791B_ABST
Abstract
Description
[0001] This application is a divisional application based on Chinese patent application No. 201580030591.X. Technical Field
[0002] In various aspects, the present invention relates to immunotherapy for treating or preventing pathologies associated with microbial infection in vertebrates, including the use of microbial vaccines. Background Art
[0003] The innate and adaptive immune systems work together in vertebrates to protect them from infection by microbial pathogens (among many other things). Antimicrobial vaccines can be formulated to engage both the innate and adaptive immune systems, but it is generally believed that an effective response to vaccination involves a specific adaptive response to one or more immunogens present in the vaccine. Thus, multivalent vaccines, such as some pneumococcal vaccines, can be used to elicit a specific adaptive response to more than one serotype. Vaccines that confer some degree of cross-protective immunity have been described, wherein cross-reactivity to antigens other than the immunogens confers a degree of protective immunity to heterologous microorganisms. SUMMARY OF THE INVENTION
[0004] In one aspect, the invention provides methods and compositions for treating a condition in a vertebrate subject characterized by pathology associated with a microbial infection involving the use of a microbial vaccine derived from one pathogenic organism to treat an infection caused by a heterologous pathogenic organism.
[0005] As non-limiting examples, the present application provides the following embodiments:
[0006] Embodiment 1. A method of modulating the immune system in a vertebrate host to therapeutically or prophylactically treat infection of a target tissue by a first microbial pathogen, comprising administering to an administration site an effective amount of an antigenic preparation comprising an antigenic determinant specific for a second heterologous microbial pathogen.
[0007] Embodiment 2. A method according to embodiment 1, wherein the formulation is administered as continuous doses given at dose intervals of at least one hour such that two or more doses are administered over a dose duration of at least one week over a period of 2 days to 1 month.
[0008] Embodiment 3. The method of embodiment 1 or 2, wherein the first microbial pathogen is Streptococcus pneumoniae or Pseudomonas aeruginosa.
[0009] Embodiment 4. The method of any one of Embodiments 1-3, wherein the second heterologous microbial pathogen is Klebsiella pneumoniae.
[0010] Embodiment 5. A method according to any one of embodiments 1-4, wherein the target tissue is the lung.
[0011] Embodiment 6. The method of Embodiment 1 or 2, wherein the first microbial pathogen is adherent invasive Escherichia coli.
[0012] Embodiment 7. The method of Embodiment 1, 2 or 6, wherein the second heterologous microbial pathogen is non-adherent, non-invasive Escherichia coli.
[0013] Embodiment 8. The method of Embodiment 1 or 2, wherein the first microbial pathogen is enterotoxigenic Escherichia coli.
[0014] Embodiment 9. The method of Embodiment 1, 2 or 8, wherein the second heterologous microbial pathogen is non-enterotoxigenic Escherichia coli.
[0015] Embodiment 10. A method according to any one of embodiments 1, 2, 6, 7, 8 or 9, wherein the target tissue is the gastrointestinal tract.
[0016] Embodiment 11. The method of Embodiment 1 or 2, wherein the first microbial pathogen is Salmonella enterica.
[0017] Embodiment 12. The method of Embodiment 1, 2 or 11, wherein the second heterologous microbial pathogen is Escherichia coli.
[0018] Embodiment 13. A method according to any one of embodiments 1, 2, 11 or 12, wherein the target tissue is the peritoneal cavity.
[0019] Embodiment 14. The method of Embodiment 1 or 2, wherein the first microbial pathogen is Pseudomonas aeruginosa.
[0020] Embodiment 15. The method of Embodiment 1, 2 or 14, wherein the second heterologous microbial pathogen is Staphylococcus aureus.
[0021] Embodiment 16. The method of embodiment 1, 2, 14 or 15, wherein the target tissue is skin.
[0022] Embodiment 17. The method of embodiment 1 or 2, wherein the target tissue is X and the second heterologous microbial pathogen is Y:
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029] Embodiment 18. The method of any one of embodiments 1-17, wherein the administration site is the skin or subcutaneous tissue.
[0030] Embodiment 19. The method of any one of embodiments 1-17, wherein the administration site is the intestine.
[0031] Embodiment 20. The method of any one of embodiments 1-17, wherein the site of administration is non-enteral.
[0032] Embodiment 21. The method of any one of Embodiments 1-17, wherein the administration site is the respiratory tract.
[0033] Embodiment 22. The method of any one of Embodiments 1-21, wherein the administration site is not the target tissue.
[0034] Embodiment 23. A method according to any one of Embodiments 1-22, wherein the antigen preparation comprises whole killed or attenuated cells or whole killed or attenuated viruses of the second heterologous microbial pathogen.
[0035] Embodiment 24. The method of any one of Embodiments 1-23, wherein the dosage duration is at least two weeks.
[0036] Embodiment 25. The method of any one of Embodiments 1-24, wherein the antigen preparation is administered such that each dose is effective to induce a local inflammatory immune response at the site of administration.
[0037] Embodiment 26. The method according to embodiment 25, wherein the antigen preparation is administered such that visible local inflammation occurs at the site of administration within 1 to 48 hours.
[0038] Embodiment 27. The method according to embodiment 26, wherein the antigen preparation is administered subcutaneously every day or every other day.
[0039] Embodiment 28. The method of any one of embodiments 1-27, wherein the formulation is administered at a dosage regimen effective to provide protective immunity to infection by the first microbial pathogen.
[0040] Embodiment 29. The method of any one of Embodiments 1-28, wherein the host is a human patient.
[0041] Embodiment 30. The method of embodiment 29, wherein the patient is immunosuppressed or immunocompromised.
[0042] Embodiment 31. The method according to embodiment 29 or 30, wherein the patient is an elderly patient.
[0043] Embodiment 32. The method of embodiment 29 or 30, wherein the patient is a pediatric patient.
[0044] Embodiment 33. A method according to any one of embodiments 29-32, wherein the patient is at risk for nosocomial infection.
[0045] Embodiment 34. Use of an antigenic preparation comprising an antigenic determinant specific for a heterologous microbial pathogen for modulating the immune system in a vertebrate host at an administration site to therapeutically or prophylactically treat infection by a first microbial pathogen in a target tissue, wherein the heterologous microbial pathogen is a second microbial pathogen different from the first microbial pathogen.
[0046] Embodiment 35. Use of an antigenic determinant specific for a heterologous microbial pathogen formulated at an administration site for modulating the immune system in a vertebrate host to therapeutically or prophylactically treat infection by a first microbial pathogen in a target tissue, wherein the heterologous microbial pathogen is a second microbial pathogen different from the first microbial pathogen.
[0047] Embodiment 36. An antigenic preparation comprising an antigenic determinant specific for a heterologous microbial pathogen, the antigenic preparation being used to modulate the immune system in a vertebrate host at an administration site to therapeutically or prophylactically treat infection by a first microbial pathogen in a target tissue, wherein the heterologous microbial pathogen is a second microbial pathogen different from the first microbial pathogen.
[0048] Embodiment 37. A composition of antigenic determinants specific for a heterologous microbial pathogen for use in formulating an antigenic preparation for use at an administration site to modulate the immune system in a vertebrate host to therapeutically or prophylactically treat infection by a first microbial pathogen in a target tissue, wherein the heterologous microbial pathogen is a second microbial pathogen different from the first microbial pathogen.
[0049] Embodiment 38. The use, composition or formulation according to any one of embodiments 34-37, wherein the formulation is used as continuous doses given with a dose interval of at least one hour such that two or more doses are administered over a period of 2 days to 1 month with a dose duration of at least one week.
[0050] Embodiment 39. The use, composition or formulation of any one of Embodiments 34-38, wherein the first microbial pathogen is Streptococcus pneumoniae or Pseudomonas aeruginosa.
[0051] Embodiment 40. The use, composition or formulation of any one of Embodiments 34-39, wherein the second heterologous microbial pathogen is Klebsiella pneumoniae.
[0052] Embodiment 41. The use, composition or formulation of any one of Embodiments 34-40, wherein the target tissue is the lung.
[0053] Embodiment 42. The use, composition or formulation of any one of Embodiments 34-38, wherein the first microbial pathogen is adherent invasive Escherichia coli.
[0054] Embodiment 43. The use, composition or formulation of any one of Embodiments 34-38 or 42, wherein the second heterologous microbial pathogen is non-adherent, non-invasive Escherichia coli.
[0055] Embodiment 44. The use, composition or formulation of any one of Embodiments 34-38, wherein the first microbial pathogen is enterotoxigenic Escherichia coli.
[0056] Embodiment 45. The use, composition or formulation of any one of Embodiments 34-38 or 44, wherein the second heterologous microbial pathogen is non-enterotoxigenic Escherichia coli.
[0057] Embodiment 46. The use, composition or formulation of any one of Embodiments 34-38 or 42-45, wherein the target tissue is the gastrointestinal tract.
[0058] Embodiment 47. The use, composition or formulation of any one of Embodiments 34-38, wherein the first microbial pathogen is Salmonella enterica.
[0059] Embodiment 48. The use, composition or formulation of any one of Embodiments 34-38 or 47, wherein the second heterologous microbial pathogen is Escherichia coli.
[0060] Embodiment 49. The use, composition or formulation of any one of Embodiments 34-38, 47 or 48, wherein the target tissue is the peritoneal cavity.
[0061] Embodiment 50. The use, composition or formulation of any one of Embodiments 34-38, wherein the first microbial pathogen is Pseudomonas aeruginosa.
[0062] Embodiment 51. The use, composition or formulation of any one of Embodiments 34-38 or 50, wherein the second heterologous microbial pathogen is Staphylococcus aureus.
[0063] Embodiment 52. The use, composition or formulation of any one of embodiments 34-38, 50 or 51, wherein the target tissue is skin.
[0064] Embodiment 53. The use, composition or formulation of any one of Embodiments 34-38, wherein the target tissue is X and the second heterologous microbial pathogen is Y:
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071] Embodiment 54. The use, composition or formulation according to any one of embodiments 34-53, wherein the administration site is the skin or subcutaneous tissue.
[0072] Embodiment 55. The use, composition or formulation according to any one of embodiments 34-53, wherein the administration site is the intestine.
[0073] Embodiment 56. The use, composition or formulation of any one of embodiments 34-17, wherein the site of administration is non-enteral.
[0074] Embodiment 57. The use, composition or formulation of any one of Embodiments 34-53, wherein the site of administration is the respiratory tract.
[0075] Embodiment 58 The use, composition or formulation according to any one of embodiments 34-57, wherein the administration site is not the target tissue.
[0076] Embodiment 59. The use, composition or formulation of any one of Embodiments 34-58, wherein the antigenic preparation comprises whole killed or attenuated cells or whole killed or attenuated viruses of the second heterologous microbial pathogen.
[0077] Embodiment 60. The use, composition or formulation of any one of Embodiments 34-59, wherein the dosage duration is at least two weeks.
[0078] Embodiment 61. The use, composition or formulation of any one of Embodiments 34-60, wherein the antigenic preparation is administered such that each dose is effective to induce a local inflammatory immune response at the site of administration.
[0079] Embodiment 62. The use, composition or formulation of Embodiment 61, wherein the antigenic preparation is administered such that visible local inflammation occurs at the site of administration within 1 to 48 hours.
[0080] Embodiment 63. The use, composition or formulation according to Embodiment 62, wherein the antigen preparation is administered subcutaneously every day or every other day.
[0081] Embodiment 64. The use, composition or formulation of any one of Embodiments 34-63, wherein the formulation is administered at a dosage regimen effective to provide protective immunity to infection by the first microbial pathogen.
[0082] Embodiment 65. The use, composition or formulation of any one of Embodiments 34-64, wherein the host is a human patient.
[0083] Embodiment 66. The use, composition or formulation of Embodiment 65, wherein the patient is immunosuppressed or immunocompromised.
[0084] Embodiment 67. The use, composition or formulation of Embodiment 65 or 66, wherein the patient is an elderly patient.
[0085] Embodiment 68. The use, composition or formulation of Embodiment 65 or 66, wherein the patient is a pediatric patient.
[0086] Embodiment 69. The use, composition or formulation of any one of Embodiments 65-68, wherein the patient is at risk of nosocomial infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] Figure 1Shown are the numbers of inflammatory monocytes and dendritic cells in the draining lymph nodes, lungs and spleen of mice following treatment with a K. pneumoniae antigenic composition or PBS as described in Example 1A herein.
[0088] Figure 2 Shown are the total numbers of monocytes and dendritic cells in the lungs, peritoneum, and spleen of mice following treatment with a K. pneumoniae antigenic composition, an Escherichia coli (E. coli) antigenic composition, or PBS as described in Example 1B herein.
[0089] Figure 3 Shown are the total numbers of CD4+ T cells, CD8+ T cells, and NK cells from mice treated with a Klebsiella pneumoniae antigenic composition, an Escherichia coli antigenic composition, or PBS as described in Example 1B herein.
[0090] Figure 4 Shown are the total numbers of (A) inflammatory monocytes and dendritic cells and (B) CD4+ T cells, CD8+ T cells, and NK cells from mice treated with heat-killed K. pneumoniae antigenic composition, phenol-killed K. pneumoniae antigenic composition, or PBS as described in Example 1C herein.
[0091] Figure 5 Shown are the relative frequencies of CD11b+Gr-1+ cells detected from the colons of mice treated with K. pneumoniae or E. coli antigenic compositions or with PBS control.
[0092] Figure 6 Shown are the relative frequencies of CD11b+Gr-1+ cells detected from the lungs of mice treated with K. pneumoniae or E. coli antigenic compositions or with PBS control.
[0093] Figure 7 Microbial prevention as discussed in Example 3 is demonstrated, wherein treatment with a composition comprising whole killed Klebsiella pneumoniae cells provides protective immunity against subsequent challenge with Streptococcus pneumoniae (S. pneumoniae). Figure 7 A is the survival curve 5 days after the attack. Figure 7 B illustrates quantification of S. pneumoniae in nasal wash, lung and spleen homogenates. Megakaryocytes were counted in ten adjacent high-power fields (400X magnification) of spleen tissue sections. Statistical significance was determined by two-tailed Mann-Whitney test.
[0094] Figure 8Demonstration As discussed in Example 4, heterologous antimicrobial therapy in a mouse model, wherein treatment with a composition comprising whole killed E. coli cells is effective in ameliorating infection caused by a heterologous strain of adherent invasive E. coli.
[0095] 9 illustrates heterologous antimicrobial therapy in a mouse model, as discussed in Example 3, wherein treatment with a composition comprising whole-killed Klebsiella pneumoniae cells is effective in ameliorating lung infection caused by Pseudomonas aeruginosa (PA14).
[0096] Fig.10 Demonstration As discussed in Example 3, heterologous antimicrobial therapy in a mouse model, wherein treatment with a composition comprising whole killed Klebsiella pneumoniae cells was effective in ameliorating lung infection caused by S. pneumoniae (P1542).
[0097] Fig.11 Demonstration As discussed in Example 5, heterologous antimicrobial therapy in a mouse model, wherein treatment with a composition comprising whole killed E. coli cells was effective in ameliorating peritoneal infection caused by S. enterica.
[0098] Fig.12 Heterologous antimicrobial therapy in a mouse model was demonstrated as discussed in Example 5, wherein the efficacy of treatment with two different compositions comprising a whole-killed Escherichia coli cell replacement strain was compared to the efficacy of treatment with an antigenic Salmonella enterica composition in ameliorating peritoneal infection caused by Salmonella enterica.
[0099] Fig.13 is a bar graph illustrating heterologous antimicrobial therapy in a mouse model as discussed in Example 6, showing the efficacy of a S. aureus derived SSI (QBSAU) against a P. aeruginosa challenge in the skin, with a significant reduction in P. aeruginosa bacterial counts following QBSAU pre-treatment.
[0100] Fig.14 is a bar graph illustrating that heterologous antimicrobial therapy in a mouse model, as discussed in Example 6, replicates and confirms Fig.13 Data shown, which demonstrate the efficacy of S. aureus derived SSI (QBSAU) against P. aeruginosa challenge in skin, show a significant reduction in P. aeruginosa bacterial counts following QBSAU pre-treatment.
[0101] Fig.15is a bar graph illustrating heterologous antimicrobial therapy in a mouse model as discussed in Example 3c, demonstrating that K. pneumoniae SSI (QBKPN) exhibits statistically superior prophylactic efficacy compared to E. coli SSI (QBECO) in protecting against P. aeruginosa challenge in the lungs.
[0102] Fig.16 is a bar graph illustrating heterologous antimicrobial therapy in a mouse model as discussed in Example 3c, demonstrating that K. pneumoniae SSI (QBKPN) exhibits statistically superior prophylactic efficacy compared to E. coli SSI (QBECO) in protecting against S. pneumoniae challenge in the lungs.
[0103] Fig.17 are two graphs showing targeted heterologous antimicrobial therapy in an aged mouse model of lung infection, showing that Klebsiella pneumoniae SSI (QBKPN) protects against S. pneumoniae challenge in the lungs of aged mice. For the survival benefit of aged mice, Fig.17 B, Comparison of young mice, Fig.17 A, more significant.
[0104] Fig.18 is a graph illustrating that QBKPN SSI reduces weight loss in aged mice following challenge with S. pneumoniae, and that this benefit is greater for aged mice than for young mice.
[0105] Fig.19 Illustrating intraperitoneal antimicrobial prophylaxis, the graph shows that both QBECO and QBKPN SSI were protective as measured by bacterial burden in the spleen, with counts in mice treated with QBECO material being significantly lower than those treated with QBKPN (data are CFU / ml (mean + / - standard deviation). DETAILED DESCRIPTION OF THE INVENTION
[0106] In all fields, the present invention relates to surprising discovery, use the preparation that is included in the antigenic determinant of pathogenic microorganism pathogen in specific tissue or organ, effectively in the pathology relevant to heterologous microorganism infection in treating this specific tissue or organ.Composition of the present invention can be used for example at the site away from infection site.Therefore, the invention provides to be derived from these microorganism pathogens, comprise complete killing of bacterium, virus or fungal species or its combination, for therapeutic or preventive treatment heterologous microorganism infection antigen composition, and the method for using antigen composition.As described in more detail below, said composition can for example be derived from endogenous pathogen or exogenous pathogen.
[0107] Can produce antigen composition of the present invention, it comprises common specificity or its peculiar antigenic determinant to microbial pathogen.In this case, if will use antigenic determinant by the appropriate mode with this effect with " specificity ", then antigenic determinant is fully for can be used for improving the immunne response of pathogen in patient body, as peculiar to the pathogen of adaptive immune response.Will recognize that antigenic determinant does not need to have so specificity, so that it is only a specific strain of pathogen or species peculiar, because even can with heterologous infection in the tissue or organ residing for the specific immune response of specific pathogen also be other close biological cross reaction of natural pathogenicity and be target preparation or selection antigen composition.
[0108] "Cell" is the basic structural and functional unit of living organisms. In higher organisms, such as animals, cells with similar structures and functions are often aggregated into "tissues" that perform specific functions. Therefore, a tissue includes a collection of similar cells and surrounding intercellular matrix, such as epithelial tissue, connective tissue, muscle, nerve. An "organ" is a fully differentiated structural and functional unit in higher organisms that can be composed of different types of tissues and specialized for a specific function, such as the kidney, heart, brain, liver, etc. Therefore, the use of "specific organ, tissue or cell" in this article is intended to include any specific organ, and includes the cells and tissues found in that organ.
[0109] A "pathogenic" agent is an agent known to cause infection in a host in nature, such as a bacterium or virus, and in this sense, "pathogenic" is used in the context of the present invention to mean "naturally pathogenic." Although a wide variety of microorganisms are capable of causing infection under artificial conditions, such as artificial inoculation of microorganisms into tissues, the range of microorganisms that naturally cause infection is necessarily limited and established through medical practice.
[0110] "Infection" is a state or condition in which the body or a part thereof is invaded by a pathogenic agent (e.g., a microorganism, such as a bacterium), which, under favorable conditions, reproduces and produces deleterious effects (Taber's Cyclopedic Medical Dictionary, 14th edition, CL Thomas, ed., FA Davis Company, PA, USA). Infection may not always be clinically evident and may result in only localized cell damage. If the body's defense mechanisms are effective, the infection may remain subclinical and transient. Infection may spread locally and become clinically evident as an acute, subacute or chronic clinical infection or disease state. Local infection may also become systemic when the pathogenic agent enters the lymphatic or vascular system. Infection is usually accompanied by inflammation, but inflammation may occur without infection.
[0111] "Inflammation" is a characteristic tissue response to injury (marked by swelling, redness, heat, and pain), and includes the continuum of changes that occur in living tissue when it is injured. Infection and inflammation are different conditions, although one can be caused by the other (Taber's Cyclopedic Medical Dictionary, supra). Thus, inflammation can occur without infection and infection can occur without inflammation (although inflammation is usually caused by pathogenic bacteria or viral infection). Inflammation is characterized by the following symptoms: redness (flushing), heat (burning), swelling (infection), pain (pain). Locally visible inflammation on the skin is evident from a combination of these symptoms, particularly redness at the site of application.
[0112] Each subject can be treated according to alternative aspects of the present invention. As used herein, a "subject" is an animal, such as a vertebrate such as a mammal, to which the specific pathogenic bacteria, bacterial antigens, viruses, viral antigens or combinations thereof of the present invention can be applied. Therefore, the subject can be a patient, such as a person, who suffers from a microbial infection, or is suspected of having a microbial infection, or is at risk of developing a microbial infection. The subject can also be an experimental animal, such as an animal infection model. In some embodiments, the terms "subject" and "patient" are used interchangeably and can include people, non-human mammals, non-human primates, rats, mice, dogs, etc. A healthy subject can be a person who has not suffered from an infection or is not suspected of having an infection, or who has not suffered from a chronic condition or illness. A "healthy subject" can also be a subject who is not immunocompromised. By "immunocompromised" or "immunosuppression" is meant any situation in which the immune system functions in an abnormal or incomplete manner, such as a patient in which the host cannot respond normally to an infection due to an impaired or weakened immune system. Immunocompromised or immunosuppression may be due to a disease, a certain agent (such as a chemotherapeutic agent for cancer treatment) or a disease present at birth. Immunocompromised subjects may be found more frequently in infants, the elderly, and individuals undergoing extensive drug or radiation therapy. Thus, aspects of the invention relate to the treatment of pediatric and elderly patients or patients at risk for nosocomial infection. Specific patient populations may include, for example, patients with compromised immune systems due to HIV infection or AIDS, cancer, solid organ transplantation, stem cell transplantation, sickle cell disease or asplenia, congenital immunodeficiency, chronic inflammatory disorders, cochlear implants, or cerebrospinal fluid leaks.
[0113] "Immune response" includes, but is not limited to, one or more of the following responses in a mammal: after administration of the composition, induction or activation of antibodies, neutrophils, monocytes / macrophages (including M1 macrophages and M2 macrophages as described herein), B cells, T cells (including helper T cells, natural killer cells, cytotoxic T cells, γδT cells), for example, induced or activated by the antigen in the antigen composition. Therefore, the immune response to the composition generally includes the development of a cell and / or antibody-mediated response to the target composition in the host animal. In some embodiments, the immune response also results in slowing down or stopping the progression of infection in the animal. The immune response includes cellular and humoral immune responses of both the innate and adaptive immune systems.
[0114] In selected embodiments, the methods of the invention may involve determining whether an individual has been previously infected with a pathogen that is pathogenic in a particular organ or tissue; and administering to the individual a therapeutic composition comprising antigenic determinants selected or formulated to be collectively specific for at least one pathogen.
[0115] On the other hand, the present invention provides a method for preparing a composition of the present invention for treating a condition characterized by a microbial disease or infection in a specific organ or tissue of an individual. The method may involve determining whether an individual has previously been infected with at least one pathogen that is pathogenic in a specific organ or tissue; producing an antigen composition comprising antigenic determinants that are specific to the at least one pathogen in common; and preparing the antigen composition for administration as a therapeutic or antimicrobial composition capable of causing an immune or antimicrobial response to a heterologous microorganism in a specific organ or tissue.
[0116] The methods for determining whether a subject has been previously exposed to a pathogen as described in detail herein may involve identifying the presence of at least one antibody that recognizes the pathogen. The methods may also or alternatively involve identifying at least one memory B cell that recognizes the pathogen. The methods may also or alternatively involve identifying at least one memory T cell that recognizes the pathogen. The methods may, for example, involve obtaining antibodies, memory B cells, or memory T cells from the peripheral circulation or from a targeted specific organ or tissue of an individual.
[0117] On the other hand, the present invention provides a method for prophylactically treating an infection in a specific organ or tissue of an individual, which involves administering an infectious microorganism to cause a reinforced infection in the organ or tissue. The method may, for example, involve administering to the individual an infectious dose of at least one pathogen that is pathogenic in a specific organ or tissue, such as an attenuated pathogen; and administering to the individual an antimicrobial composition comprising an antigenic determinant, the antigenic determinant being selected or formulated so that it is jointly specific to the at least one pathogen, such as a composition comprising a fully killed pathogen, so as to treat or prevent infection by a heterologous microorganism. The method may involve these two administration steps that are performed simultaneously. The method may involve a second step that is performed between 1 hour and 30 days after the first step.
[0118] The compositions of the present invention can be formulated or used, for example, at sites away from the specific organ or tissue targeted for treatment, for example, by subcutaneous or intradermal injection. The compositions can be formulated, for example, for repeated administration, for example, by subcutaneous or intradermal injection. In selected embodiments, the compositions of the present invention can be formulated or used so as to produce a local immune response at the site of administration, for example, at a skin injection site.
[0119] In selected embodiments, pathogens can be selected for use in the methods and compositions of the present invention based on pathogens endogenous to a specific organ or tissue of targeted therapy. Alternatively, the pathogen can be exogenous to a specific organ or tissue. The pathogen can be formulated to attenuate or kill pathogens, for example to provide an antigenic composition that is fully attenuated or kills pathogens. For example, the pathogen can be a bacterium, virus, protozoa, fungus or parasite.
[0120] On the other hand, a method for preparing an antimicrobial composition for treating a disease characterized by infection in a specific organ or tissue is provided. The method may involve selecting at least one pathogen that is pathogenic in a specific organ or tissue; producing an antigen composition comprising antigenic determinants that are specific to the pathogen together; and preparing the antigen composition for use as an antimicrobial composition capable of causing an antimicrobial response to a heterologous microorganism in a specific organ or tissue.
[0121] The method may also involve a diagnostic step to identify the specific organ or tissue in which the infection is symptomatic, prior to producing the antigenic composition.
[0122] Optionally, the antigen composition can be formulated for subcutaneous injection or intradermal injection. Optionally, the antigen composition can be formulated for injection to produce a local skin immune response at the site of application. Optionally, the method described in detail herein is provided so that when determining a specific tissue or organ, a pathogen is selected from a group of specific pathogens described herein. On the one hand, the pathogen is an endogenous biological pathogen, which is the natural cause of infection in the tissue or organ in question. Optionally, the pathogen is an exogenous organism for the natural cause of infection in the tissue or organ in question, and can include, for example, bacteria, viruses, parasites or fungi.
[0123] Optionally, the antigen composition can be formulated for repeated subcutaneous or intradermal administration. Optionally, the antigen composition can be formulated for administration by parenteral route. Optionally, the pathogen described in detail herein is a bacterium, virus, protozoa, fungus or parasite. Further, the method may involve killing or attenuating the pathogen so that the antigen composition is formulated into a fully killed or attenuated pathogen composition. The pathogen is a member of an endogenous flora species, which is the natural cause of infection in a specific organ or tissue. The pathogen may be an exogenous species, which is the natural cause of infection in a specific organ or tissue.
[0124] On the other hand, a method for treating an illness characterized by infection or a pathology related to microbial infection in a specific organ or tissue of an individual is provided. The method relates to an antimicrobial composition comprising an antigenic determinant to be used by an individual. The antigenic determinant is selected or prepared so that it is specific to at least one pathogenic pathogen in a specific organ or tissue. Optionally, the antimicrobial composition can be used in a continuous dose given at a dosage interval between one hour and one month at the site of application, in a dosage duration of at least two weeks. Further, but not limited to, administration may include, for example, 1,2,3,4,5 or 6 days to 1,2,3,4, 5 or 6 weeks, two or more dosages (or 10 or more, or 100 or more).
[0125] In another aspect, the use of an antimicrobial composition for treating a condition characterized by inflammation in a specific organ or tissue of an individual is disclosed. The antimicrobial composition may, for example, contain antigenic determinants selected or formulated to be specific to at least one microbial pathogen that is pathogenic in a specific organ or tissue.
[0126] On the other hand, the use of an antimicrobial composition for preparing a medicament for treating a disease characterized by an infection-related pathology in a specific organ or tissue of an individual is disclosed. The antimicrobial composition, for example, may contain an antigenic determinant selected or formulated to be specific to at least one microbial pathogen that is pathogenic in a specific organ or tissue.
[0127] On the one hand, a method for comparing immune responses is provided. The method involves administering a medicament with an antigen composition to an animal having an organ or tissue, the antigen composition having an antigenic determinant selected or formulated so that the antigenic determinant is specific to at least one microbial pathogen that is pathogenic in the organ or tissue, extracting a quantifiable immune sample from the organ or tissue, measuring the immune response characteristics in the organ or tissue in the quantifiable immune sample after the medicament is administered, and comparing the immune response characteristics in the quantifiable immune sample with the corresponding immune response characteristics in the reference immune sample obtained from the corresponding organ or tissue. Optionally, the reference immune sample can be obtained from the corresponding organ or tissue in the animal before the step of administering the medicament. Optionally, the reference immune sample can be obtained from the corresponding organ or tissue in the second animal. Optionally, the animal can have an infection in the organ or tissue.
[0128] Comparing immune response characteristics may involve comparing quantifiable and reference immune samples, any one or more of the following cell numbers: inflammatory monocytes, macrophages, CD11b+ Gr-1+ cells, dendritic cells, CD11c+ MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Further, comparing immune response characteristics may involve comparing the transition of macrophage activation state. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0129] Optionally, comparing immune response characteristics may involve identifying cell markers on any one or more of the following cells in the quantifiable and reference immune samples: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0130] Optionally, comparing immune response characteristics may involve identifying quantifiable and reference immune samples, any one or more of the following cells produce cytokines: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ cells, CD4+ T cells, CD8+ T cells or NK cells. As described in detail herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, cytokines are produced due to a change in the activation state of macrophages. Optionally, macrophages are transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages are transformed from M1 macrophages to M2 macrophages.
[0131] Optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in a quantifiable and reference immune sample: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, differential gene expression is produced due to a change in the activation state of macrophages. Optionally, macrophages are transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages are transformed from M1 macrophages to M2 macrophages.
[0132] Optionally, the medicament may be administered at the site of administration in continuous doses given at intervals of between one hour and one month, over a dosage duration of at least one week. Optionally, the medicament may be administered intradermally or subcutaneously. Optionally, the drug may be administered in a dose such that each dose effectively causes a visible local inflammatory immune response at the site of administration. Optionally, the medicament may be administered such that visible local inflammation occurs at the site of administration within 1 to 48 hours. Further and optionally, the animal may be a mammal. Optionally, the animal may be a human or a mouse.
[0133] On the other hand, a method for selecting a therapeutic preparation suitable for treating an infection in a specific organ or tissue of an individual is provided. The method is related to providing an animal with an infection in a specific organ or tissue, providing a test preparation with one or more antigenic determinants of a pathogenic microbial pathogen in a corresponding specific organ or tissue of a healthy individual, measuring the immune response characteristics in a reference immune sample obtained from an animal organ or tissue, administering the test preparation to the animal, measuring the immune response characteristics in a quantifiable immune sample obtained from the corresponding organ or tissue of the animal, comparing the immune response characteristics in a reference and quantifiable immune sample, and processing the immune response characteristics enhanced in a quantifiable immune sample compared to a reference immune sample, as an indication of the suitability of the test preparation as a therapeutic preparation. Optionally, the animal is killed before a quantifiable immune sample has been obtained.
[0134] Optionally, comparing immune response characteristics may involve comparing quantifiable and reference immune samples, any one or more of the following cell numbers: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve comparing the transition of macrophage activation state. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0135] Optionally, comparing immune response characteristics may involve identifying cell markers on any one or more of the following cells in the quantifiable and reference immune samples: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0136] Optionally, comparing immune response characteristics may involve identifying cytokines produced by any one or more of the following cells in a quantifiable and reference immune sample: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, cytokines are produced due to a change in the activation state of macrophages. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0137] Further and optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in a quantifiable and reference immune sample: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, differential gene expression may be produced due to a change in the activation state of macrophages. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0138] On the other hand, a method for selectively targeting an infected tissue or organ of a human subject with an immune response is provided. The method relates to administering to a subject a medicament having an effective amount of a microbial pathogen antigen composition, wherein the microbial pathogen may be pathogenic in a specific organ or tissue of the subject, wherein there is an infection caused by a heterologous microorganism in the subject, and the antigen composition comprises antigenic determinants that are specific to the microbial pathogen in common. Optionally, the antigen composition may include a fully killed bacterial cell composition. Optionally, the medicament may be administered at an amount and time that effectively raises the antimicrobial immune response in an organ or tissue of a subject with an infection caused by a heterologous microorganism. Optionally, the method may also relate to measuring the characteristics of an immune response. The method also includes the preventive treatment of infection by immune protective vaccination.
[0139] On the other hand, a method for treating an infection in a tissue or organ of a human subject or a pathology associated with a microbial infection is provided. The method involves administering to the subject an antigen composition containing a microbial pathogen in an effective amount, such as a medicament that kills all bacterial cells or a viral composition, wherein the microbial pathogen is pathogenic in a specific organ or tissue of the subject where the heterologous microbial infection is located or to prevent future infection. The medicament can be administered to the subject in an amount and time that effectively regulates the immune response in the target organ or tissue. In this way, the present invention provides a site-specific immunomodulator (SSI) that causes an immune response in a target organ or tissue. In selected embodiments, the target organ or tissue may be different from or away from the site of administration. Optionally, the regulation of the immune response may involve a transition in the activation state of macrophages. Optionally, the regulation of the immune response may involve a transition from an M2 macrophage response to an M1 macrophage response. As those terms are defined herein, the regulation of the immune response may involve a transition from an M1 macrophage to an M2 macrophage. Optionally, but not limited to, the method may also involve measuring immune response characteristics.
[0140] Optionally, comparing immune response characteristics may involve comparing quantifiable and reference immune samples, any one or more of the following cell numbers: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve comparing the transition of macrophage activation state. Further and optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0141] Further, but not limited to, comparing immune response characteristics may involve identifying quantifiable and reference immune samples, cell markers on any one or more of the following cells: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ cells, CD4+ T cells, CD8+ T cells or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve identifying quantifiable and reference immune samples, cytokines produced by any one or more of the following cells: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Further, cytokines are produced due to a change in the activation state of macrophages. The macrophages may be transformed from M2 macrophages to M1 macrophages. Optionally, the macrophages may be transformed from M1 macrophages to M2 macrophages.
[0142] Further and optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in a quantifiable and reference immune sample: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, differential gene expression may be produced due to a change in the activation state of macrophages. Further and optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Macrophages may be transformed from M1 macrophages to M2 macrophages.
[0143] In another aspect, a method for monitoring the efficacy of a therapeutic regimen in an individual treating an infection in a specific organ or tissue is provided. The method involves measuring an immune response signature in a post-treatment immune sample obtained from a specific organ or tissue after the individual has been subjected to the therapeutic regimen for a period of time, wherein the presence of an immune response signature that is greater in magnitude than would be expected for an individual who has not been subjected to the therapeutic regimen indicates that the therapeutic regimen is effective; and the therapeutic regimen involves administering a formulation comprising one or more antigenic determinants of a microbial pathogen that is pathogenic in the corresponding specific organ or tissue of a healthy subject.
[0144] The methods described in detail herein may also involve measuring the immune response characteristics in a pre-treatment reference sample, wherein the pre-treatment reference sample is obtained before, at the same time or after the start of the treatment regimen, but before obtaining the post-treatment immune sample, and comparing the immune response characteristics in the pre-treatment and post-treatment samples, wherein the increase in the magnitude of the immune response in the post-treatment immune sample compared to the pre-treatment reference sample indicates that the treatment regimen is effective. Optionally, measuring the immune response characteristics may involve determining an indication of the number of inflammatory monocytes in a sample of the organ or tissue. Optionally, measuring the immune response characteristics may involve determining an indication of the number of macrophages in a sample of the organ or tissue. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0145] As described in detail in another aspect of this paper, the present invention also provides a method for preparing an immunogenic composition for treating an infection in a mammal, such as a specific organ or tissue of a human patient. The method may include selecting at least one microbial pathogen that is naturally pathogenic in a mammalian organ or tissue where a heterologous microorganism is infected. Antigenic compositions may be produced that include antigenic determinants that are specific or unique to microbial pathogens.
[0146] The diagnostic step can be used to identify the specific organ or tissue where the infection is located before the antigen composition targeting the injection site is produced. The injection site can be a primary site, or a secondary site of transfer. The antigen composition can have sufficient specificity to enable it to cause a specific immune response to the microbial pathogen in a mammal. The antigen composition can be a bacterial composition, for example, derived from a bacterial species endogenous to the patient's flora or from an exogenous species. In an alternative embodiment, the antigen composition can be derived from a virus or multiple viruses. Therefore, the microbial pathogen from which the antigen composition is derived can be a virus. The microbial pathogen can be killed. In an alternative embodiment, the microbial pathogen can be live or attenuated. The immunogenic composition of the present invention can also be configured or applied in an antimicrobial manner, such as an NSAID. The application site can be a site away from the injection site, for example, in an organ or tissue that is not an organ or tissue where a heterologous infection is located, such as the skin or subcutaneous tissue.
[0147] Antigen composition for example can be prepared for subcutaneous injection, intradermal injection or oral administration.In the embodiment of subcutaneous or intradermal injection, the administration of adjustable antigen composition or preparation so that in the skin of application site, produce local immune response, for example, after using 2-48 hour, there is the inflammation zone that diameter is 2mm to 100mm and continues, for example 2-72 hour or longer.Antigen composition can be prepared for repeated subcutaneous or intradermal administration, for example, in alternating continuity site.
[0148] In some embodiments, the present invention relates to a method for treating an infection in a mammal in a tissue or organ. In alternative embodiments, treatment may precede the development of heterologous infection in a tissue, for example, if the primary infection site indicates the possibility that the infection will spread to a specific tissue or organ, then the patient may be treated prophylactically to prevent or improve the transfer to the tissue or organ. The method may include administering an effective amount of an antigen composition to the subject, the antigen composition comprising an antigenic determinant that is specific to at least one microbial pathogen in common. One aspect of the present invention relates to using a microbial pathogen that is pathogenic in a specific organ or tissue of a mammal where the heterologous infection is located. The antigen composition may be administered at the site of administration, for example, by subcutaneous or intradermal injection, in a continuous dose given at a dosage interval between one hour and one month, for example, at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4 or 5 years or longer dosage duration. For example, each injection dose may be measured so that it effectively causes, for example, visible local inflammation that occurs after 1-48 hours of injection at the site of administration.
[0149] In another aspect, methods are provided for treating a heterologous infection of a specific organ or tissue in a subject by administering one or more antigens of one or more microbial pathogens, such as bacterial, viral or fungal species, that are pathogenic in the specific organ or tissue.
[0150] In alternative embodiments, pathogenic microorganism species may be able to cause infection naturally (that is, without human intervention) in the specific organs or tissues of healthy subjects, or may have caused infection in the specific organs or tissues of healthy subjects. In alternative embodiments, the antigen can be used by using the preparation of the whole cell derived from microbial species. In alternative embodiments, the method may for example include using at least two or more microbial species, or using at least three or more microbial species, and the microorganism may be a bacterium or a virus. In alternative embodiments, the method may also include using a supplement or an adjuvant. One aspect of the present invention relates to using antigen composition so as to cause an immune response in the experimenter.
[0151] In alternative embodiments, the microbial pathogen in the antigen composition can be killed, and therefore can cause it to be non-infectious. In some embodiments, the antigen composition is used at a site away from a heterologous infection site, and in selected this type of embodiment, method of the present invention can be implemented so that it does not produce infection at a heterologous infection site.
[0152] As described in detail herein, various aspects of the present invention relate to treating heterologous infections. In this case, treatment can be implemented so as to provide a variety of results. For example, treatment can: cause an immune response that effectively inhibits or ameliorates the growth or spread of infection; inhibit the growth or proliferation of heterologous microorganisms; cause infection remission; improve quality of life; reduce the risk of recurrence of infection; inhibit the spread of infection; or, improve patient survival in a patient population. In this case, extending the life expectancy of a patient or patient population means increasing the number of patients who survive a specified period of time after a specific diagnosis. In some embodiments, treatment may be a patient who has not yet responded to other treatments, such as a patient for whom chemotherapy or surgery is not an effective treatment. Treatment in alternative embodiments may, for example, be before or after the onset of a heterologous infection. For example, prophylactic treatment may be performed, such as a patient diagnosed as being at risk for a specific heterologous infection.
[0153] Bacteria and bacterial colonization and infection
[0154] Most animals are colonized to some extent by other organisms, such as bacteria, which often exist in a symbiotic or commensal relationship with the host animal. Thus, many generally harmless bacterial species are found in healthy animals and are often localized to the surfaces of specific organs and tissues. Often, these bacteria contribute to the normal functioning of the body. For example, in humans, symbiotic Escherichia coli bacteria can be found in the intestines, where they promote immunity and reduce the risk of infection by more virulent pathogens.
[0155] Generally harmless bacteria, such as Escherichia coli, can cause infection in healthy subjects, with results ranging from mild to severe infection to death. Whether a bacterium is pathogenic (i.e., causes infection) depends to a certain extent on factors such as the entry pathways and channels to reach specific host cells, tissues or organs; the inherent toxicity of the bacteria; the amount of bacteria present at the potential infection site; or the health of the host animal. Therefore, in view of the favorable conditions for infection, generally harmless bacteria can become pathogenic, and even the most virulent bacteria require a specific environment to cause infection. Therefore, microbial species that are members of the normal flora can be pathogens when they exceed their normal ecological role in the endogenous flora. For example, endogenous species can cause infection outside the niche of their anatomical adjacent areas, such as through contact transmission. When this happens, these generally harmless endogenous bacteria are considered pathogenic.
[0156] Specific bacterial species and viruses are known to cause infection in specific cells, tissues or organs of otherwise healthy subjects. Examples of bacteria and viruses that commonly cause infection in specific organs and tissues of the body are listed below; it should be understood that these examples are not intended to be limiting and that the skilled person will be able to easily identify and identify the infectious or pathogenic bacteria that cause infection, or commonly cause infection, in various organs and tissues of healthy adults (and identify the relative frequency of infection by each bacterial species) based on the knowledge in the field presented by, for example, the following publications: Manual of Clinical Microbiology, 8th edition, Patrick Murray, ed., 2003, ASM Press American Society for Microbiology, Washington DC, USA; Mandell, Douglas and Bennett, Principles and Practice of Infectious Diseases, 5th edition, GL Mandell, JE Bennett, R. Dolin, ed., 2000, Churchill Livingstone, Philadelphia, PA, USA, all of which are incorporated herein by reference.
[0157] Skin infections are usually caused by the following bacterial species: Staphylococcus aureus, group A, B, C, or G beta-hemolytic streptococci, Corynebacterium diptheriae, Corynebacterium ulcerans, or Pseudomonas aeruginosa; or viral pathogens: measles, rubella, varicella-zoster, echovirus, coxsackievirus, adenovirus, vaccinia, herpes simplex, or parvovirus B19.
[0158] Soft tissue infections (eg, fat and muscle) are usually caused by bacterial species such as Streptococcus pyogenes, Staphylococcus aureus, Clostridium perfringens, or other Clostridium species, or viral pathogens such as influenza or coxsackievirus.
[0159] Breast infections are usually caused by the following bacterial species: Staphylococcus aureus or Streptococcus pyogenes.
[0160] Infections of the head and neck lymph nodes are usually caused by the following bacterial species: Staphylococcus aureus or Streptococcus pyogenes; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, herpes simplex, coxsackievirus, or varicella-zoster.
[0161] Arm / axillary lymph node infections are usually caused by the following bacterial species: Staphylococcus aureus or Streptococcus pyogenes; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, adenovirus, or varicella-zoster.
[0162] Mediastinal lymph node infections are usually caused by the following bacterial species: viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Fusobacterium spp., or Mycobacterium tuberculosis; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, or adenovirus.
[0163] Hilar lymph node infections are usually caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Chlamydophila pneumoniae, Bordetella pertussis, or Mycobacterium tuberculosis; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
[0164] Intra-abdominal lymph node infections are usually caused by the following bacterial species: Yersinia enterocolitica, Yersinia pseudotuberculosis, Salmonella spp., Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, or Mycobacterium tuberculosis; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, varicella-zoster, adenovirus, influenza, or coxsackievirus.
[0165] Infections of the lymph nodes in the leg / groin area are usually caused by the following bacterial species: Staphylococcus aureus or Streptococcus pyogenes; or viral pathogens: measles, rubella, Epstein-Barr, cytomegalovirus, or herpes simplex.
[0166] Bloodstream infections (i.e., sepsis) are usually caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, coagulase-negative staphylococci, Enterococcus spp., Escherichia coli, Klebsiella spp., Enterobacter spp., Proteus spp., Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus pneumoniae, or Group B Streptococcus; or viral pathogens: measles, rubella, varicella-zoster, echovirus, coxsackievirus, adenovirus, Epstein-Barr, herpes simplex, or cytomegalovirus.
[0167] Bone infections are usually caused by the following bacterial species: Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, other Streptococci spp., Escherichia coli, Pseudomonas spp., Enterobacter spp., Proteus spp., or Serratia spp.; or viral pathogens: parvovirus B19, rubella, or hepatitis B.
[0168] Joint infections are commonly caused by the following bacterial species: Staphylococcus aureus, coagulase-negative staphylococci, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, other Streptococcus species, Escherichia coli, Pseudomonas species, Enterobacter species, Proteus species, Serratia species, Neisseria gonorrhoeae, Salmonella species, Mycobacterium tuberculosis, Haemophilus influenzae; or viral pathogens: parvovirus B19, rubella, hepatitis B; or fungal pathogens: Scedosporium prolificans.
[0169] Meningeal infections are usually caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, or Listeria monocytogenes; or viral pathogens: echoviruses, coxsackieviruses, other enteroviruses, or mumps.
[0170] Brain infections are usually caused by the following bacterial species: certain Streptococcus species (including S. anginosus, S. constellatus, S. intermedius), Staphylococcus aureus, certain Bacteroides species, certain Prevotella species, certain Proteus species, Escherichia coli, certain Klebsiella species, certain Pseudomonas species, certain Enterobacter species, or Borrelia burgdorferi; or viral pathogens: coxsackievirus, echovirus, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flavivirus, or bunyavirus.
[0171] Spinal cord infections are usually caused by the following bacterial species: Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus agalactiae, Listeria monocytogenes, or Borrelia burgdorferi; or viral pathogens: coxsackievirus, echovirus, poliovirus, other enteroviruses, mumps, herpes simplex, varicella-zoster, flavivirus, or bunyavirus.
[0172] Ocular / orbital infections are usually caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus milleri, Escherichia coli, Bacillus cereus, Chlamydia trachomatis, Haemophilus influenzae, Pseudomonas spp., Klebsiella spp., or Treponema pallidum; or viral pathogens: adenovirus, herpes simplex, varicella-zoster, or cytomegalovirus.
[0173] Salivary gland infections are usually caused by the following bacterial species: Staphylococcus aureus, viridans streptococci (e.g., Streptococcus salivarius, Streptococcus sanguis, Streptococcus mutans), certain species of Peptostreptococcus, or certain species of Bacteroides, or other oral anaerobes; or viral pathogens: mumps, influenza, enterovirus, or rabies.
[0174] Oral infections are usually caused by the following bacterial species: Prevotella melaninogenicus, anaerobic Streptococcus, viridans Streptococcus, Actinomyces spp., Peptostreptococcus spp., or Bacteroides spp. or other oral anaerobes; or viral pathogens: herpes simplex, coxsackievirus, or Epstein-Barr virus.
[0175] Tonsillar infections are usually caused by the following bacterial species: Streptococcus pyogenes or group C or G B-hemolytic Streptococci; or viral pathogens: rhinovirus, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
[0176] Sinus infections are usually caused by the following bacterial species: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, alpha-streptococci, anaerobic bacteria (such as certain species of Prevotella), or Staphylococcus aureus; or viral pathogens: rhinovirus, influenza, adenovirus, or parainfluenza.
[0177] Nasopharyngeal infections are usually caused by the following bacterial species: Streptococcus pyogenes or group C or G B-hemolytic Streptococci; or viral pathogens: rhinovirus, influenza, coronavirus, adenovirus, parainfluenza, respiratory syncytial virus, or herpes simplex.
[0178] Thyroid infections are usually caused by bacterial species such as Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus pneumoniae; or viral pathogens such as mumps or influenza.
[0179] Throat infections are usually caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Streptococcus pyogenes; or viral pathogens: rhinovirus, influenza, parainfluenza, adenovirus, coronavirus, or human metapneumovirus.
[0180] Tracheal infections are usually caused by the following bacterial species: Mycoplasma pneumoniae; or viral pathogens: parainfluenza, influenza, respiratory syncytial virus, or adenovirus.
[0181] Bronchial infections are usually caused by the following bacterial species: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Bordetella pertussis, Streptococcus pneumoniae, or Haemophilus influenzae; or viral pathogens: influenza, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus.
[0182] Lung infections are usually caused by the following bacterial species: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, or Haemophilus influenzae; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
[0183] Pleural infections are usually caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Bacteroides fragilis, Prevotella spp., Fusobacterium nucleatum, Peptostreptococcus spp., or Mycobacterium tuberculosis; or viral pathogens: influenza, adenovirus, respiratory syncytial virus, or parainfluenza.
[0184] Mediastinal infections are usually caused by bacterial species such as viridans streptococci, Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., Clostridium spp., or Mycobacterium tuberculosis; or viral pathogens such as measles, rubella, Epstein-Barr, or cytomegalovirus.
[0185] Cardiac infections are usually caused by the following bacterial species: certain species of Streptococcus (including S. mitior, S. bovis, S. sanguis, S. mutans, S. anginosus), certain species of Enterococcus, certain species of Staphylococcus, Corynebacterium diphtheriae, Clostridium perfringens, Neisseria meningitidis, or certain species of Salmonella; or viral pathogens: enterovirus, coxsackievirus, echovirus, poliovirus, adenovirus, mumps, measles, or influenza.
[0186] Esophageal infections are usually caused by bacterial species such as Actinomyces, Mycobacterium avium, Mycobacterium tuberculosis, or Streptococcus; or viral pathogens such as cytomegalovirus, herpes simplex, or varicella-zoster.
[0187] Gastric infections are usually caused by the following bacterial species: Streptococcus pyogenes or Helicobacter pylori; or viral pathogens: cytomegalovirus, herpes simplex, Epstein-Barr, rotavirus, norovirus, or adenovirus.
[0188] Small intestinal infections are usually caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteriditis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenovirus, astrovirus, calicivirus, norovirus, rotavirus, or cytomegalovirus.
[0189] Colon / rectal infections are usually caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteritidis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenovirus, astrovirus, calicivirus, norovirus, rotavirus, or cytomegalovirus.
[0190] Anal infections are usually caused by bacterial species such as Streptococcus pyogenes, Bacteroides spp., Clostridium spp., anaerobic Streptococci, Clostridium spp., Escherichia coli, Enterobacter spp., Pseudomonas aeruginosa, or Treponema pallidum; or by viral pathogens such as herpes simplex.
[0191] Perineal infections are usually caused by the following bacterial species: Escherichia coli, certain Klebsiella species, certain Enterococcus species, certain Bacteroides species, certain Clostridium species, certain Clostridium species, certain Clostridium species, certain Pseudomonas aeruginosa, anaerobic Streptococci, certain Clostridium species, or certain Enterobacter species; or viral pathogens: herpes simplex.
[0192] Liver infections are usually caused by the following bacterial species: Escherichia coli, certain species of Klebsiella, Streptococcus (angina type), certain species of Enterococcus, other viridans streptococci, or certain species of Bacteroides; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, measles, varicella-zoster, coxsackievirus, or adenovirus.
[0193] Gallbladder infections are usually caused by the following bacterial species: Escherichia coli, Klebsiella species, Enterobacter species, Enterococcus, Bacteroides species, Clostridium species, Clostridium species, Salmonella enteritidis, Yersinia enterocolitica, or Shigella flexneri.
[0194] Biliary tract infections are usually caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterobacter spp., Enterococci, Bacteroides spp., Clostridium spp., Clostridium spp., Salmonella enteritidis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: hepatitis A, Epstein-Barr, herpes simplex, mumps, rubella, measles, varicella-zoster, coxsackievirus, or adenovirus.
[0195] Pancreatic infections are usually caused by the following bacterial species: Escherichia coli, Klebsiella spp., Enterococcus spp., Pseudomonas spp., Staphylococcus spp., Mycoplasma spp., Salmonella typhi, Leptospira spp., or Legionella spp.; or viral pathogens: mumps, coxsackievirus, hepatitis B, cytomegalovirus, herpes simplex 2, or varicella-zoster.
[0196] Splenic infections are usually caused by the following bacterial species: certain Streptococcus species, certain Staphylococcus species, certain Salmonella species, certain Pseudomonas species, certain Escherichia coli, or certain Enterococcus species; or viral pathogens: Epstein-Barr, cytomegalovirus, adenovirus, measles, rubella, coxsackievirus, or varicella-zoster.
[0197] Adrenal gland infections are usually caused by bacterial species such as Streptococcus, Staphylococcus, Salmonella, Pseudomonas, Escherichia coli, or Enterococcus, or by viral pathogens such as varicella-zoster.
[0198] Kidney infections are usually caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Providentia spp., Morganella spp., Enterococcus faecalis, or Pseudomonas aeruginosa; or viral pathogens: BK virus or mumps.
[0199] Ureteral infections are usually caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Providencia species, Morganella species, or Enterococcus species.
[0200] Bladder infections are usually caused by the following bacterial species: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Providencia, Morganella, Enterococcus faecalis, or Corynebacterium jejuni; or viral pathogens: adenovirus or cytomegalovirus.
[0201] Peritoneal infections are usually caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, Klebsiella spp., Proteus spp., Enterococci, Bacteroides fragilis, Prevotella nigrofaciens, Peptococcus spp., Peptostreptococcus spp., Clostridium spp., or Clostridium spp.
[0202] Retroperitoneal infections are usually caused by the following bacterial species: Escherichia coli or Staphylococcus aureus.
[0203] Prostate infections are usually caused by the following bacterial species: Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Enterococcus, Pseudomonas, Corynebacterium, or Neisseria gonorrhoeae; or viral pathogens: herpes simplex.
[0204] Testicular infections are usually caused by the following bacterial species: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus, Streptococcus, or Salmonella enteritidis; or viral pathogens: mumps, coxsackievirus, or lymphocytic choriomeningitis virus.
[0205] Penile infections are usually caused by the following bacterial species: Staphylococcus aureus, Streptococcus pyogenes, Neisseria gonorrhoeae, or Treponema pallidum; or viral pathogens: herpes simplex.
[0206] Ovarian / appendage infections are usually caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardnerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp., Streptococcus spp., or Escherichia coli.
[0207] Uterine infections are usually caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, Gardenerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp., Streptococcus spp., or Escherichia coli.
[0208] Cervical infections are usually caused by the following bacterial species: Neisseria gonorrhoeae, Chlamydia trachomatis, or Treponema pallidum; or viral pathogens: herpes simplex.
[0209] Vaginal infections are usually caused by bacterial species such as Gardnerella vaginalis, Prevotella spp., Bacteroides spp., Peptococcus spp., Escherichia coli, Neisseria gonorrhoeae, Chlamydia trachomatis, or Treponema pallidum; or by viral pathogens such as herpes simplex.
[0210] Vulvar infections are usually caused by bacterial species such as Staphylococcus aureus, Streptococcus pyogenes, or Treponema pallidum; or viral pathogens such as herpes simplex.
[0211] Bacterial strain / Viral subtype
[0212] Those skilled in the art will appreciate that bacterial species are operationally classified as collections of similar strains (which generally refer to a population of assumed common ancestors with identifiable physiological but usually not morphological differences, and which can be identified using serological techniques directed against bacterial surface antigens). Thus, each bacterial species (e.g., S. pneumoniae) has many strains (or serotypes) that may differ in their ability to cause infection or in their ability to cause infection in a particular organ / site. For example, while there are at least 90 serotypes of S. pneumoniae, serotypes 1, 3, 4, 7, 8, and 12 are most commonly responsible for pneumococcal disease in humans.
[0213] As a second example, certain strains of E. coli, called extraintestinal pathogenic E. coli (ExPEC), are more likely to cause urinary tract infections or other extraintestinal infections such as neonatal meningitis, while other strains, including enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), Shiga toxin-producing E. coli (STEC), enteroaggregative E. coli (EAEC), enteroinvasive E. coli (EIEC), and diffusely adherent E. coli (DAEC) are more likely to cause gastrointestinal infections / diarrhea. Even within the ExPEC strain subclass, specific virulence factors (e.g., production of type 1 fimbriae) make certain strains more capable of causing bladder infections, while other virulence factors (e.g., production of P fimbriae) make other strains more capable of causing infections in the kidneys. According to the present invention, for a formulation targeting bladder infection, an ExPEC strain that is more likely to cause infection in the bladder may be selected, while for a formulation targeting kidney infection, an ExPEC strain that is more likely to cause infection in the kidney may be selected. Similarly, for a formulation treating colon infection, one or more of the ETEC, EPEC, EHEC, STEC, EAEC, EIEC or DAEC strains of Escherichia coli (i.e., strains that cause colon infection) may be selected.
[0214] Similarly, there may be many subtypes of specific viruses.For example, there are three types of influenza, influenza A, influenza B and influenza C, which are different in epidemiology, host range and clinical characteristics.For example, influenza A is more likely to be relevant to viral lung infection, and influenza B is more likely to be relevant to myositis (that is, muscle infection).In addition, each of these three types of influenza viruses has many subtypes, which also may be different in epidemiology, host range and clinical characteristics.According to the present invention, the influenza A subtype most often associated with lung infection can be selected to infect with a targeted heterologous lung, and the influenza B strain most often associated with myositis can be selected to treat the infection of muscle / soft tissue.
[0215] It will be appreciated that a clinical microbiologist skilled in the art will therefore be able to select strains of a particular bacterial species (or a particular viral subtype) to target a particular organ or tissue based on this disclosure and the body of knowledge in the art regarding bacterial strains of each bacterial species. Thus, the present invention provides site-specific immunomodulators (SSIs) in the sense that the formulations and treatments of the present invention elicit an immune response in a target organ or tissue, and the target may be different from or remote from the site of administration.
[0216] Microbial compositions, dosages and administration
[0217] The composition of the present invention includes antigens of pathogenic pathogenic microorganisms (bacteria or viruses) species that are pathogenic in specific tissues or organs. The composition may include whole bacterial species, or may include extracts or preparations of pathogenic bacterial species of the present invention, such as cell wall or cell membrane extracts or whole cells or exotoxins, or whole cells and exotoxins. The composition may also include one or more separated antigens from one or more pathogenic bacterial species of the present invention; in some embodiments, such compositions may be useful in the case of specific antigens that may have to be accurately administered in a specific dose, or may be useful if the administration of whole bacterial species or its components (such as toxins) may be harmful. Pathogenic bacterial species are commercially available (e.g., from ATCC (Manassas, VA, USA), or may be clinical isolates from subjects with bacterial infections (e.g., pneumonia) of tissues or organs.
[0218] The microbial composition of the present invention can be provided in a form suitable for administration to mammals, such as humans, alone or in combination with other compounds (e.g., nucleic acid molecules, small molecules, peptides or peptide analogs) in the presence of liposomes, adjuvants or any pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carriers" or "excipients" include any and all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. The carrier can be suitable for any appropriate form of administration, including subcutaneous, intradermal, intravenous, parenteral, intraperitoneal, intramuscular, sublingual, inhaled, intratumoral or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injections or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active compound (i.e., the specific bacteria, bacterial antigens or compositions thereof of the present invention), their use in the pharmaceutical composition of the present invention is considered. Supplementary active compounds can also be incorporated into the composition.
[0219] Conventional pharmaceutical practice can be used to provide suitable formulations or compositions for administering the compound to a subject suffering from an infection. Any suitable route of administration can be used, such as parenteral, intravenous, intradermal, subcutaneous, intramuscular, intracranial, intraorbital, ocular, intraventricular, intracapsular, intraspinal, intrathecal, intracisternal, intraperitoneal, intranasal, inhalation, aerosol, topical, intratumoral, sublingual or oral administration. The therapeutic formulation can be in the form of a liquid solution or suspension; for oral administration, the formulation can be in the form of a tablet or capsule; for intranasal formulations, in the form of powders, nasal drops or aerosols; and for sublingual formulations, in the form of drops, aerosols or tablets.
[0220] Methods for preparing formulations known in the art are found, for example, in "Remington's Pharmaceutical Sciences" (20th edition), A. Gennaro, 2000, Mack Publishing Company, Easton, PA. Formulations for parenteral administration, for example, may contain excipients, sterile water or saline, polyalkylene glycols (such as polyethylene glycol), oils of plant origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compound. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate, and deoxycholate, or may be oily solutions for use in the form of nasal drops, or as gels. For therapeutic or prophylactic compositions, the pathogenic bacterial species is administered to an individual in an amount effective to stop or slow the progression of infection, or increase the survival of the subject.
[0221] The "effective amount" of the pathogenic microorganism species or its antigen of the present invention includes a therapeutically effective amount or a prophylactic effective amount. "Therapeutically effective amount" refers to the amount that achieves the expected therapeutic result, such as reducing or eliminating heterologous infection, preventing microbial infection process, slowing tumor growth, or increasing survival time beyond the effective amount of survival time predicted using, for example, the SEER database, at the necessary dosage and time period. The therapeutically effective amount of pathogenic microorganism (bacteria or virus) species or its antigen can be changed according to factors such as individual disease state, age, sex and weight, and the ability of the compound to cause the expected response in the individual. The dosage regimen can be adjusted to provide the best therapeutic response. The therapeutically effective amount can also be the amount in which any toxic or harmful effects of the pathogenic bacterial species or its virus or antigen are exceeded by the beneficial effects of the treatment. "Prophylactic effective amount" refers to the amount that achieves the expected preventive result, such as preventing infection, slowing the progression of infection, reducing or eliminating the effective amount of heterologous microbial cells, at the necessary dosage and time period.
[0222] For administration by subcutaneous or intradermal injection, exemplary ranges of therapeutically or prophylactically effective amounts of one or more pathogenic bacterial species may be about 1 million to 100 billion organisms per milliliter, or 100 million to 7 billion organisms per milliliter, or 500 million to 6 billion organisms per milliliter, or 1 billion to 5 billion organisms per milliliter, or 2 billion to 4 billion organisms per milliliter, or any integer within these ranges. The total concentration of bacteria per milliliter may range from 1 million to 100 billion organisms, or 50 million to 7 billion organisms per milliliter, or 100 million to 6 billion organisms per milliliter, or 500 million to 5 billion organisms per milliliter, or 1 billion to 4 billion organisms per milliliter, or any integer within these ranges. A therapeutically or prophylactically effective amount of an antigen of a pathogenic bacterial species may range from any integer of 0.1 nM to 0.1 M, 0.1 nM to 0.05 M, 0.05 nM to 15 μM, or 0.01 nM to 10 μM.
[0223] It is worth noting that the dosage concentration and range can vary with the severity of the disease to be alleviated, or can vary with the immune response of the subject. In general, the goal is to achieve a sufficient immune response. For administration by subcutaneous or intradermal infection, the extent of the immune response can be determined, for example, by the size of the local immune skin reaction delayed by the injection site (e.g., 0.25 inches to 4 inches in diameter). The dosage required to achieve an appropriate immune response can be varied according to the individual (and its immune system) and the desired response. Standardized doses can also be used. In the case of subcutaneous or intradermal administration, if the goal is to achieve a local skin reaction of 2 inches, the total dose of the bacterial composition, for example, can range from 2 million bacteria (e.g., 0.001 ml of a composition with a concentration of 2 billion organisms per ml) to more than 20 billion bacteria (e.g., 1 ml of a composition with a concentration of 20 billion organisms per ml). The concentration of a single bacterial species or its antigen in the composition can also be considered. For example, if the concentration of a particular pathogenic bacterial species, the cell size of the species or its antigenic load is much higher than other pathogenic bacterial species in the composition, the local immune skin reaction of the individual is likely to be due to its response to this particular bacterial species. In some embodiments, for example, depending on the exposure history to a particular species infection in the past, the immune system of the individual may respond more strongly to a bacterial species in the composition than other species, so the dosage or composition can be adjusted accordingly for the individual. However, in some embodiments described in detail herein, the immune response will not be monitored by means of skin reactions. For example, in some mouse models utilized herein, the effective treatment of such animals with an antigen composition may not cause a corresponding skin reaction. It will be appreciated by those skilled in the art that, in addition to relying on the presence or absence of a skin reaction, there is an alternative way to monitor the immune response.
[0224] For any particular subject, the time and dosage of treatment can be adjusted over time according to individual needs and the professional judgment of the person administering or supervising the administration of the composition (for example, the time can be daily, every other day, weekly, monthly). For example, in the case of subcutaneous or intradermal administration, the composition can be administered once every two days. An initial dose of approximately 0.05 ml can be administered subcutaneously, followed by an increase of 0.01-0.02 ml every two days until a sufficient skin reaction is achieved at the injection site (for example, a delayed reaction of 1 inch to 2 inches of visible redness at the injection site). Once this sufficient immune response is achieved, administration is continued in this manner according to the maintenance dose. The maintenance dose can be adjusted from time to time to achieve an expected visible skin reaction (inflammation) at the injection site. Administration can be performed for a duration of, for example, at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4 or 5 years or longer.
[0225] Oral dosages may range from 10 million to 1 trillion organisms per dose containing antigenic determinants of one or more species. Oral dosages may be given, for example, 4 times a day, once a day, or once a week. Administration may be performed, for example, for a duration of at least 1 week, 2 weeks, 2 months, 6 months, 1, 2, 3, 4, or 5 years or longer.
[0226] In some embodiments, the present invention may include sublingual or by inhalation administration, or simultaneously or sequentially administered to one or more epithelial tissues (i.e., administered to the skin by intradermal or subcutaneous injection; administered to pulmonary epithelial cells by inhalation; administered to gastrointestinal mucosa by oral ingestion; administered to oral mucosa by sublingual administration). Therefore, in some embodiments, the antigen composition of the present invention is administered to cause an immune response in epithelial tissue. In some embodiments, one or more epithelial administration routes may be combined with one or more other administration routes, such as intratumoral, intramuscular or intravenous administration.
[0227] In various aspects of the present invention, the antigen composition used to the patient can be characterized as having an antigenic marker, that is, a combination of fully specific antigens or epitopes so that the antigen composition can cause a specific immune response, such as an acquired immune response, to a specific pathogen. The surprising and unexpected aspect of the present invention is the non-adaptive or non-specific activation of a specific antigen composition-mediated immune response in which these treatments are effective for heterologous infections in pathogenic tissues of a specific pathogen.
[0228] The routes of administration and dosage ranges proposed herein are exemplary only and do not limit the routes of administration and dosage ranges that can be selected by a medical practitioner. The amount of active compound (e.g., pathogenic bacterial species or its virus or antigen) in the composition can be changed according to factors such as individual disease state, age, sex and weight. The dosage regimen can be adjusted to provide the best therapeutic response. For example, a single bolus can be administered, several divided doses can be administered over time, or the dosage can be reduced or increased in proportion as indicated by the emergency state of the treatment situation. It may be advantageous to formulate the parenteral composition into a dosage unit form for ease of administration and uniformity of dosage.
[0229] In the case of antigen preparations (i.e. preparations that cause immune responses), it is possible to provide, alone or in combination with other compounds, such as immunoadjuvants, a compound or composition of the present invention with an immunogenic effective amount. The compound may also be connected to a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity. Antigenic compositions are compositions comprising materials that cause a desired immune response. Antigenic compositions may be selected, activated or expanded, but are not limited to: memory B, T cells, neutrophils, monocytes or macrophages of the immune system, such as to reduce or eliminate the growth or proliferation of heterologous microorganisms. In some embodiments, the specific pathogenic microorganisms, viruses, viral antigens, bacteria, bacterial antigens or compositions thereof of the present invention can cause an expected immune response when any other reagent is lacking, and therefore can be considered as antigen compositions. In some embodiments, antigen compositions may include suitable carriers, such as adjuvants, which are agents that act in a non-specific manner to enhance an immune response to a specific antigen or to a group of antigens, so that the amount of antigen in any given dose can be reduced, or the dosage frequency required to produce an expected immune response can be reduced. Bacterial antigen compositions may include live or dead bacteria that can induce an immune response to an antigenic determinant that is usually associated with bacteria. In some embodiments, antigen composition can include as attenuated strain (attenuation), and therefore causes the live bacteria of not too serious infection.In some embodiments, antigen composition can include can induce live, attenuated or dead virus for the immunne response of the antigenic determinant usually associated with virus.
[0230] Antigen compositions comprising killed bacteria for administration by injection can be prepared as follows. Bacteria can be grown in suitable culture medium and washed with physiological saline solution. Centrifugal bacteria are then resuspended in saline solution and heat-killed. The suspension can be standardized by direct microscopic counting, mixed in the required amount, and stored in a suitable container, and its safety, shelf life and sterility can be tested in an approved manner. Except pathogenic bacteria species and / or its antigen, the killing bacteria composition suitable for use in humans can include 0.4% phenolic preservatives and / or 0.9% sodium chloride. The bacterial composition can also include a trace of brain heart infusion (beef), peptone, yeast extract, agar, sheep blood, dextrose, sodium phosphate and / or other culture medium components.
[0231] In some embodiments, the bacterial or microbial composition may be in tablet or capsule form or in drops for oral ingestion, as an aerosol for inhalation, or in drops, aerosol or tablet form for sublingual administration.
[0232] In the antigen composition that comprises bacterium, the concentration of specific bacterial species in the composition for subcutaneous or intradermal injection can be about 1 million to 100 billion organisms per milliliter, or can be 100 million to 7 billion organisms per milliliter, or can be 500 million to 6 billion organisms per milliliter, or can be 1 billion to 5 billion organisms per milliliter, or can be 2 billion to 4 billion organisms per milliliter, or any integer in these scopes.The total concentration scope of every milliliter of bacterium can be 1 million to 100 billion organisms, or can be 500 million to 7 billion organisms per milliliter, or can be 100 million to 6 billion organisms per milliliter, or can be 500 million to 5 billion organisms per milliliter, or can be 1 billion to 4 billion organisms per milliliter, or any integer in these scopes.
[0233] In some embodiments, an antigenic microbial composition for treating an infection at a specific site (e.g., an infection of lung tissue) may include pathogenic microorganisms that usually, more often, or most often cause infection in that tissue or organ (e.g., an infection in lung tissue, i.e., pneumonia).
[0234] In general, pathogenic bacterial species of the present invention and antigens thereof should be used without producing significant toxicity. Standard techniques can be used, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e. the ratio of LD50 (dose that is lethal to 50% of the population) and LD100 (dose that is lethal to 100% of the population) to determine the toxicity of the compounds of the present invention.
[0235] As described herein and in one aspect of the present invention, a method for comparing or eliciting a specific immune response is provided. The method involves administering a medicament having an antigenic composition as described herein to an animal having an organ or tissue. The antigenic composition may have antigenic determinants selected or formulated so that the antigenic determinants are collectively specific to at least one microbial pathogen that is pathogenic in the organ or tissue, extracting a quantifiable immune sample from the organ or tissue, measuring the immune response characteristics in the organ or tissue in the quantifiable immune sample after administration of the medicament, and comparing the immune response characteristics in the quantifiable immune sample with the corresponding immune response characteristics in a reference immune sample obtained from the corresponding organ or tissue. As used herein, the immune sample will contain sufficient biological material to determine the characteristics of the immune response. As used herein, the "characteristics" of the immune response may include, but are not limited to, the specific number of specific immune cell types (e.g., macrophages) or specific cell markers (e.g., upregulation of integrins) or gene products (e.g., cytokines). The foregoing is provided as an example and is not limiting.
[0236] Optionally, the reference immune sample can be obtained from a corresponding organ or tissue in an animal prior to the step of administering the agent. On the other hand, the reference immune sample can be obtained from a corresponding organ or tissue in a second animal, making it particularly contemplated that at least two animals (i.e., an animal from which the reference immune sample is obtained and a second animal from which the quantifiable immune sample is obtained) can be used in the methods described herein. Optionally, the animal can have an infection in said organ or tissue.
[0237] Comparing immune response characteristics may involve comparing an indication of the number of any one or more of the following cells in a quantifiable and reference immune sample, as these cells are known to those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, the macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0238] Macrophages can be defined as "M1 macrophages" or "M2 macrophages". For example, those skilled in the art generally believe that M1 macrophages promote Th1 CD4+ T cell-mediated responses (see, e.g., Biswas and Mantovani (2010), Nature Immunology 10:889-96). Moreover, M1 macrophages are generally believed to have effective antigen presentation capabilities and are good at killing intracellular pathogens (e.g., viruses). Moreover, M1 macrophages are generally believed to be good at playing an immune role in tumor destruction, at least compared to M2 macrophages. Those skilled in the art will recognize that there are many biomarkers that can be used to distinguish between M1 macrophages and M2 macrophages. For example, and as described in detail herein, compared to M2 macrophages, the expression of Nos2 is generally believed to be associated with M1 macrophages (see, e.g., Laskin et al. (2010) Annual Rev. Pharmacol. Toxicol. 51:267-288). Further, and for example, it is generally believed that M1 macrophages produce IL-12 and are efficiently activated by IFN-γ via the IFN-γR (Biswas and Mantovain, supra).
[0239] In contrast to M1 macrophages, M2 macrophages promote Th2 CD4+ T cell-mediated responses (see generally: Biswas and Mantovani (2010), Nature Immunology 10:889-96). Moreover, M2 macrophages are generally considered to be efficient and encapsulate and clear extracellular parasites, etc. Further, and compared to M1 macrophages, those skilled in the art generally believe that M2 macrophages are more effective in T cell responses. reg The expression of Nos2 is generally considered to be associated with M2 macrophages. For example, and as described herein, compared with the higher expression usually found in M1 macrophages, it is generally considered that the weakened Nos2 expression is associated with M2 macrophages. Further, and as described in detail in experiments herein, it is generally considered that the expression of CD206 is associated with M2 macrophages (see, for example, Choi et al. (2010) Gastroenterology 138 (7) 2399-409). Further, and as described in detail in experiments herein, it is generally considered that the expression of F4 / 80 is associated with M2 macrophages. Further, and for example, it is generally considered that M2 macrophages can be effectively activated by IL-4 or IL-13 through IL-4Rα (Biswas and Mantovain, supra).
[0240] Further, comparing immune response characteristics may involve comparing changes in macrophage activation states. Changes in macrophage activation states may optionally be characterized as changes from M2 macrophages to M1 macrophages or vice versa. Those skilled in the art will recognize that there are many biomarkers that can be used to monitor macrophage activation. As described in detail herein, those skilled in the art will recognize that defining macrophages as being activated for M1 macrophages or M2 macrophages can be achieved by selecting markers known to be associated with any of the phenotypes described herein.
[0241] Optionally, comparing immune response characteristics may involve identifying cell markers on any one or more of the following cells in the quantifiable and reference immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Those skilled in the art will recognize that there are many cell markers (both extracellular and intracellular) that can be selected to identify immune responses. Further, and as described herein, the marker CD206 is generally considered to be associated with M2 macrophages (see, e.g., Choi et al. (2010) Gastroenterology 138(7)2399-409).
[0242] Optionally, comparing immune response characteristics may involve identifying cytokines produced by any one or more of the following cells in the quantifiable and reference immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Those skilled in the art will recognize that cytokines refer to small cell signaling protein molecules and there are many cytokines known in the art. For example, cytokines have been divided into type 1 and type 2 categories based on their role in immune response. Common type 1 cytokines include IFN-γ and TGF-β. Common type 2 cytokines include, but are not limited to, IL-4 and IL-13. Cytokines can be detected by many methods known to those skilled in the art. For example, and as described in detail herein, ELISA experiments are used to determine the cytokine production of lung tissue.
[0243] As described in detail herein, the macrophages may include any one or more of the following: M1 macrophages or M2 macrophages as defined herein. Optionally, cytokines are produced due to the change in the activation state of the macrophages. Optionally, the macrophages are transformed from M2 macrophages to M1 macrophages. Further and optionally, the macrophages are transformed from M1 macrophages to M2 macrophages.
[0244] Optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in a quantifiable and reference immune sample, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+ Gr-1+ cells, dendritic cells, CD11c+ MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. The term "differential gene expression" is understood to mean a significant difference between the expression of a specific target gene from at least two experimental conditions. For example, if under a first experimental condition, as defined by a gene expression method used by those skilled in the art, a specific gene has a defined expression level and under a second experimental condition, the same gene has a significant difference in its expression level, then there is differential expression of the target gene. Those skilled in the art will appreciate that there are many methods for detecting differential gene expression. For example, as described in detail herein for determining the relative Nos2 / Arg1 ratio, commercially available quantitative PCR techniques can be used. Optionally, differential gene expression is produced due to a transition in the activation state of macrophages. Optionally, the macrophage can be converted from an M2 macrophage to an M1 macrophage, as those terms are defined herein.
[0245] In another embodiment, the medicament can be administered in a continuous dose at the administration site at a dosage interval between one hour and one month, and administered within a dosage duration of at least one week. Optionally, the medicament can be administered intradermally or subcutaneously. Optionally, the medicine can be administered in a dosage so that each dosage effectively causes a visible local inflammatory immune response at the administration site. Optionally, the medicament can be administered so that visible local inflammation occurs at the administration site within 1 to 48 hours. However, although an immune response has been triggered, there may not be a visible local inflammatory immune response in all cases. Those skilled in the art will recognize that there are other methods that can monitor the realization of immune response. For example, the properties (and relative changes in characteristics) of the immune cells from the subject who has undergone an immune response can be compared with the properties of the immune cells from the subject who has not undergone an immune response.
[0246] Further and optionally for the methods disclosed herein, the animal can be a vertebrate, such as a mammal. Optionally, the animal can be a human or a mouse.
[0247] On the other hand, a method for selecting a therapeutic preparation suitable for treating an infection in a specific organ or tissue of an individual is provided. The method is related to providing an animal with an infection in a specific organ or tissue, providing a test preparation with one or more antigenic determinants of a pathogenic microbial pathogen in a corresponding specific organ or tissue of a healthy individual, measuring the immune response characteristics in a reference immune sample obtained from an animal organ or tissue, administering the test preparation to the animal, measuring the immune response characteristics in a quantifiable immune sample obtained from the corresponding organ or tissue of the animal, comparing the immune response characteristics in a reference and quantifiable immune sample, and processing the immune response characteristics enhanced in a quantifiable immune sample compared to a reference immune sample, as an indication of the suitability of the test preparation as a therapeutic preparation. Optionally, the animal is killed before a quantifiable immune sample has been obtained.
[0248] Optionally, comparing immune response characteristics may involve comparing quantifiable and reference immune samples, any one or more of the following cell numbers, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, as those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve comparing the transition of macrophage activation state. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0249] Optionally, comparing immune response characteristics may involve identifying cellular markers on any one or more of the following cells in the quantifiable and reference immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, as those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0250] Optionally, comparing immune response characteristics may involve identifying cytokines produced by any one or more of the following cells in a quantifiable and reference immune sample: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. As those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, cytokines are produced due to a change in the activation state of macrophages. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages.
[0251] Further and optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in quantifiable and reference immune samples: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ Class cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, as those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, differential gene expression may be produced due to a change in the activation state of macrophages. Optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0252] On the other hand, a method for selectively targeting an infected tissue or organ of a human subject with an immune response is provided. The method relates to administering to a subject a medicament having an effective amount of a microbial pathogen antigen composition, wherein the microbial pathogen may be pathogenic in a specific infected organ or tissue of the subject, and the antigen composition comprises antigenic determinants that are specific to the microbial pathogen in common. Optionally, the antigen composition may include a fully killed bacterial cell composition. Optionally, the medicament may be administered to a subject at an amount and time that effectively raises the immune response in the infected organ or tissue of the subject. Optionally, the method may also relate to measuring the characteristics of an immune response.
[0253] On the other hand, a method for treating an infection in a tissue or organ of a human subject is provided. The method involves administering to the subject an agent having an effective amount of a microbial pathogen antigen composition comprising a fully killed bacterial cell composition, wherein the microbial pathogen is pathogenic in a specific organ or tissue of the subject where the infection is located. The agent can be administered to the subject in an amount and time that effectively regulates the immune response. Optionally, the regulation of the immune response may involve a change in the activation state of macrophages. Optionally, the regulation of the immune response may involve a change from an M2 type macrophage response to an M1 type macrophage response. The regulation of the immune response may involve a change from an M1 type macrophage response to an M2 type macrophage response. Optionally, the method may also involve measuring the characteristics of the immune response.
[0254] Optionally, comparing immune response characteristics may involve comparing quantifiable and reference immune samples, any one or more of the following cell quantity indications, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells or NK cells. Optionally, as those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve comparing the transition of macrophage activation state. Further and optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0255] Further and optionally, comparing immune response characteristics may involve identifying cellular markers on any one or more of the following cells in the quantifiable and reference immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+ Gr-1+ cells, dendritic cells, CD11c+ MHC II+ cells, CD4+ T cells, CD8+ T cells, or NK cells. As those terms are defined herein, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, comparing immune response characteristics may involve identifying cytokines produced by any one or more of the following cells in the quantifiable and reference immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+ Gr-1+ cells, dendritic cells, CD11c+ MHC II+ cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Further, cytokines are produced due to the change in the activation state of macrophages. Macrophages may be transformed from M2 macrophages to M1 macrophages. Optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0256] Further and optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in a quantifiable and reference immune sample, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, differential gene expression may be produced due to a change in the activation state of macrophages. Further and optionally, macrophages may be transformed from M2 macrophages to M1 macrophages. Macrophages may be transformed from M1 macrophages to M2 macrophages.
[0257] In another aspect, a method for monitoring the efficacy of a therapeutic regimen in an individual treating an infection in a specific organ or tissue is provided. The method involves measuring an immune response signature in a post-treatment immune sample obtained from a specific organ or tissue after the individual has been subjected to the therapeutic regimen for a period of time, wherein the presence of an immune response signature that is greater in magnitude than would be expected for an individual who has not been subjected to the therapeutic regimen indicates that the therapeutic regimen is effective; and the therapeutic regimen involves administering a formulation comprising one or more antigenic determinants of a microbial pathogen that is pathogenic in the corresponding specific organ or tissue of a healthy subject.
[0258] The methods described in detail herein may also involve measuring the immune response characteristics in a pre-treatment reference sample, wherein the pre-treatment reference sample is obtained before, at the same time or after the start of the treatment regimen, but before obtaining the post-treatment immune sample, and comparing the immune response characteristics in the pre-treatment and post-treatment samples, wherein the increase in the magnitude of the immune response in the post-treatment immune sample compared to the pre-treatment reference sample indicates that the treatment regimen is effective. Optionally, measuring the immune response characteristics may involve determining an indication of the number of inflammatory monocytes in a sample of the organ or tissue. Optionally, measuring the immune response characteristics may involve determining an indication of the number of macrophages in a sample of the organ or tissue. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0259] Optionally, measuring the immune response characteristics may involve determining an indication of the number of CD11b+Gr-1+ cells in a sample of the organ or tissue or determining an indication of the number of dendritic cells in a sample of the organ or tissue. Further and optionally, measuring the immune response characteristics may involve determining an indication of the number of CD11c+MHC II+ class cells in a sample of the organ or tissue or determining an indication of the number of CD4+ T cells in a sample of the organ or tissue or determining an indication of the number of CD8+ T cells in a sample of the organ or tissue.
[0260] Optionally, measuring the magnitude of the immune response may involve determining an indication of the number of NK cells in a sample of the organ or tissue. Further and optionally, comparing immune response characteristics may involve identifying cell markers on any one or more of the following cells in the reference and immune samples, as they are commonly understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Optionally, macrophages may include any one or more of the following: M1 macrophages or M2 macrophages.
[0261] Further and optionally, comparing immune response characteristics may involve identifying cytokines produced by any one or more of the following cells in the reference and immune samples, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Optionally, cytokines may be produced due to a change in the activation state of macrophages. Macrophages may be transformed from M2 macrophages to M1 macrophages. Further and optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0262] Optionally, comparing immune response characteristics may involve identifying differential gene expression produced by any one or more of the following cells in the reference and immune sample, as they are generally understood by those skilled in the art: inflammatory monocytes, macrophages, CD11b+Gr-1+ cells, dendritic cells, CD11c+MHC II+ class cells, CD4+ T cells, CD8+ T cells, or NK cells. Macrophages may include any one or more of the following: M1 macrophages or M2 macrophages. Differential gene expression may be produced due to changes in the activation state of macrophages. Macrophages may be transformed from M2 macrophages to M1 macrophages. Optionally, macrophages may be transformed from M1 macrophages to M2 macrophages.
[0263] The viral pathogen utilized herein can be, but is not limited to, influenza, adenovirus, respiratory syncytial virus, parainfluenza, monkeypox virus, herpes simplex virus (1 and 2), varicella zoster, cytomegalovirus, Epstein-Barr virus, coronavirus, human metapneumovirus, Hendra virus, Nipah virus, Hantavirus, Lassa virus, human T-cell lymphotropic virus, coxsackievirus, echovirus, enterovirus or rhinovirus, or any virus that is pathogenic in the lungs.
[0264] The bacterial pathogen utilized herein may be, but is not limited to, Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Chlamydia pneumoniae, Legionella pneumophila or Bordatella pertussis or any bacteria that is pathogenic in the lungs.
[0265] The fungal pathogens utilized herein may be, but are not limited to, Aspergillus fumigatus, Blastomyces sp., Coccidiodes immitis, Coccidiodes posadasii, Cryptococcus neoformans, Cryptococcus gattii, Fusarium sp., Histoplasma capsulatum, Paecilomyces sp., Paracoccidiodes brasiliensis, Penicillium marneffei, Pneumocystis jiroveci, Pseudallescheria boydii, Scedosporium apiospermum, Rhizopus spp. sp., Mucor sp., Absidia sp., Cunninghamella sp., Scedosporium fertile, Stachybotrys chartarum, Trichoderma longibrachiatium, Trichosporon sp., or any fungus that is pathogenic in the lung.
[0266] In various aspects, embodiments of the present invention relate to compositions comprising biological components that can cause gastrointestinal infections, such that the organism can be characterized as a pathogen. However, organisms that are pathogenic in some cases may not always cause disease. Most animals are colonized to some extent by other organisms, such as bacteria, which usually exist in a symbiotic or commensal relationship with the host animal. Therefore, many generally harmless bacterial species are found in healthy animals, and are usually localized to the surfaces of specific organs and tissues. Often, these bacteria contribute to the normal function of the body. For example, in humans, symbiotic Escherichia coli bacteria can be found in the intestines, wherein the bacteria promote immunity and reduce the risk of infection by more virulent pathogens.
[0267] Normally harmless bacteria, such as Escherichia coli, can cause infections in healthy subjects, with outcomes ranging from mild to severe infections to death. Whether an organism, such as a bacterium, is pathogenic (i.e., causes infection) depends to some extent on factors such as the pathways and passages to specific host cells, tissues, or organs; the inherent toxicity of the bacteria; the amount of bacteria present at a potential infection site; or the health of the host animal. Therefore, given favorable conditions for infection, generally harmless organisms can become pathogenic, and even virulent organisms require specific environments to cause infection. Therefore, organisms that are members of normal flora can be pathogens when they transcend their normal ecological role in endogenous flora. For example, endogenous species can cause infection outside their niches in anatomical neighborhoods, for example, through contact transmission. When this happens, and in the context of the present invention, these generally harmless endogenous organisms are considered pathogenic.
[0268] It is known that certain organisms, such as bacterial species, viruses, helminths and protozoa, can cause infection in specific areas of the GIT of otherwise healthy subjects. Examples of organisms that commonly cause infection in specific areas of the GIT are listed below; it should be understood that these examples are not intended to be limiting and that the skilled person will be able to easily identify and identify infectious or pathogenic organisms that cause infection, or commonly cause infection, in various GIT areas of healthy adults based on, for example, knowledge of specific patient populations presented in the following publications: Manual of Clinical Microbiology 8th edition, Patrick Murray, ed., 2003, ASM Press American Society for Microbiology, Washington DC, USA; Mandell, Douglas and Bennett, Principles and Practice of Infectious Diseases 5th edition, GL Mandell, JEB Bennett, R. Dolin, ed., 2000, Churchill Livingstone, Philadelphia, PA, USA, all of which are incorporated herein by reference.
[0269] Oral infections are usually caused by the following bacterial species: Prevotella nigrofaciens, anaerobic Streptococcus, viridans Streptococcus, Actinomyces spp., Peptostreptococcus spp., or Bacteroides spp. or other oral anaerobes; or viral pathogens: herpes simplex, coxsackievirus, or Epstein-Barr virus.
[0270] Esophageal infections are usually caused by bacterial species such as Actinomyces, Mycobacterium avium, Mycobacterium tuberculosis, or Streptococcus; or viral pathogens such as cytomegalovirus, herpes simplex, or varicella-zoster.
[0271] Gastric infections are usually caused by the following bacterial species: Streptococcus pyogenes or Helicobacter pylori; or viral pathogens: cytomegalovirus, herpes simplex, Epstein-Barr, rotavirus, norovirus, or adenovirus.
[0272] Small intestinal infections are usually caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteritidis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenovirus, astrovirus, calicivirus, norovirus, rotavirus, or cytomegalovirus.
[0273] Colon / rectal infections are usually caused by the following bacterial species: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteritidis, Yersinia enterocolitica, or Shigella flexneri; or viral pathogens: adenovirus, astrovirus, calicivirus, norovirus, rotavirus, or cytomegalovirus.
[0274] Anal infections are usually caused by bacterial species such as Streptococcus pyogenes, Bacteroides spp., Clostridium spp., anaerobic Streptococci, Clostridium spp., Escherichia coli, Enterobacter spp., Pseudomonas aeruginosa, or Treponema pallidum; or by viral pathogens such as herpes simplex.
[0275] Organisms such as bacteria are operationally classified as a collection of similar strains (which generally refers to a population of assumed common ancestors with identifiable physiological but usually not morphological differences, and which can be identified using serological techniques for bacterial surface antigens). Therefore, each bacterial species (e.g., Escherichia coli) has many strains (or serotypes) that may differ in their ability to cause infection or in the ability to cause infection in a specific organ / site. Certain strains of Escherichia coli are more likely to cause gastrointestinal infection / diarrhea, including enterotoxigenic Escherichia coli (ETEC), enteropathogenic Escherichia coli (EPEC), enterohemorrhagic Escherichia coli (EHEC), Shiga toxin-producing Escherichia coli (STEC), enteroaggregative Escherichia coli (EAEC), enteroinvasive Escherichia coli (EIEC), and diffusely adherent Escherichia coli (DAEC). According to the present invention, for the preparations used for treatment and heterologous microbial infections, such as GIT infections, such as IBD-related microbial infections, one or more of the ETEC, EPEC, EHEC, STEC, EAEC, EIEC or DAEC strains of Escherichia coli (i.e., strains that cause colonic infections) can be selected. For example, non-ETEC strains of Escherichia coli can be used to prepare antigenic preparations for treating infections with ETEC strains of Escherichia coli. Similarly, non-EPEC, non-EHEC, non-STEC, non-EAEC, non-EIEC or non-DAEC strains of Escherichia coli can be used to prepare antigenic preparations for treating infections with EPEC, EHEC, STEC, EAEC, EIEC or DAEC strains of Escherichia coli, respectively.
[0276] Similarly, there may be many subtypes of a particular virus, helminth, or protozoa that are associated with disease in a particular population and are therefore suitable for use in the present invention.
[0277] The composition of the present invention is included in the antigen of the organism that is pathogenic in the specific area of the body such as GIT. The composition may include the components of the whole organism, whole cell or whole virion, or may include the extract or preparation of the organism, such as cell wall or cell membrane extract, or exotoxin. The composition may also include one or more antigens separated from these organisms. Pathogenic organisms are commercially available (e.g., from American Type Culture Collection, Manassas, VA, USA), or may be clinical isolates from subjects with infection.
[0278] The composition derived from pathogens of the present invention can be provided in a form suitable for administration to mammals, such as humans, alone or in combination with other compounds (e.g., nucleic acid molecules, small molecules, peptides or peptide analogs) in the presence of liposomes, adjuvants or any pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carriers" or "excipients" include any and all physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delay agents, etc. The carrier can be suitable for any appropriate form of administration, including subcutaneous, intradermal, intravenous, parenteral, intraperitoneal, intramuscular, sublingual, inhaled or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injections or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with active compounds (i.e., specific bacteria, bacterial antigens or compositions thereof of the present invention), their use in the pharmaceutical compositions of the present invention is considered. Supplementary active compounds can also be incorporated into the composition.
[0279] Methods for preparing formulations known in the art are found, for example, in "Remington's Pharmaceutical Sciences" (20th edition), A. Gennaro, 2000, Mack Publishing Company, Easton, PA. Formulations for parenteral administration, for example, may contain excipients, sterile water or saline, polyalkylene glycols (such as polyethylene glycol), oils of plant origin, or hydrogenated naphthalene. Biocompatible, biodegradable lactide polymers, lactide / glycolide copolymers, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compound. Other potentially useful parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, such as lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate, and deoxycholate, or may be oily solutions for use in the form of nasal drops, or as gels. For therapeutic or preventive compositions, the formulation may be administered to an individual in an amount effective to prevent, terminate, or slow the progression of microbial infection.
[0280] According to the present invention, the "effective amount" of pathogenic species or its antigen includes a therapeutically effective amount or a prophylactic effective amount. "Therapeutically effective amount" refers to an amount that achieves the desired therapeutic result, such as reducing or eliminating the symptoms of microbial infection, according to the necessary dosage and time period. The therapeutically effective amount of pathogenic species or its antigen can be changed according to factors such as individual disease state, age, sex and weight, and the ability of the compound to cause the expected response in the individual. The dosage regimen can be adjusted to provide the best therapeutic response. The therapeutically effective amount can also be an amount in which any toxic or harmful effects of the pathogenic species or its antigen are exceeded by the beneficial effects of the treatment. "Prophylactic effective amount" refers to an amount that achieves the desired preventive result, such as preventing microbial infection, according to the necessary dosage and time period. Usually, a preventive dose is used in a subject before microbial infection or in the early stages so that the preventive effective amount can be lower than the therapeutically effective amount.
[0281] For administration by subcutaneous or intradermal injection, exemplary ranges of therapeutically or prophylactically effective amounts of one or more pathogenic bacterial species may be about 1 million to 100 billion organisms per milliliter, or 100 million to 7 billion organisms per milliliter, or 500 million to 6 billion organisms per milliliter, or 1 billion to 5 billion organisms per milliliter, or 2 billion to 4 billion organisms per milliliter, or any integer within these ranges. The total concentration of bacteria per milliliter may range from 1 million to 100 billion organisms, or 50 million to 7 billion organisms per milliliter, or 100 million to 6 billion organisms per milliliter, or 500 million to 5 billion organisms per milliliter, or 1 billion to 4 billion organisms per milliliter, or any integer within these ranges. A therapeutically or prophylactically effective amount of an antigen of a pathogenic bacterial species may range from any integer of 0.1 nM to 0.1 M, 0.1 nM to 0.05 M, 0.05 nM to 15 μM, or 0.01 nM to 10 μM.
[0282] It is noteworthy that dosage concentration and range can be changed with the severity of the disease to be alleviated, or can be changed with the immune response of the subject. Generally speaking, the goal is to achieve a sufficient immune response. For administration by subcutaneous or intradermal infection, the size of the local immune skin reaction delayed by the injection site (e.g., 0.25 inch to 4 inch diameter) can determine the degree of immune response. The dosage required for achieving an appropriate immune response can be changed according to the individual (and its immune system) and the required response. Standardized doses can also be used.
[0283] In the case of subcutaneous or intradermal administration, if the goal is to achieve a local skin reaction of 2 inches, then using a bacterial composition, the total dose, for example, can range from 2 million bacteria (e.g., 0.001 ml of a composition with a concentration of 2 billion organisms per ml) to more than 20 billion bacteria (e.g., 1 ml of a composition with a concentration of 20 billion organisms per ml). The concentration of a single bacterial species or its antigens in the composition can also be considered. For example, if the concentration of a particular pathogenic bacterial species, the cell size of the species or its antigen load is much higher than other pathogenic bacterial species in the antigen composition, then the local immune skin reaction of the individual is likely due to its response to this particular bacterial species. In some embodiments, for example, depending on the exposure history to a particular species infection in the past, the immune system of the individual may respond more strongly to one bacterial species in the composition than to other species, so the dose or composition can be adjusted accordingly for the individual.
[0284] For any particular subject, the time and dosage of treatment can be adjusted over time according to individual needs and the professional judgment of the personnel who administer or supervise the application of the composition (for example, the time can be daily, every other day, weekly, monthly). For example, in the case of subcutaneous or intradermal administration, the composition can be applied once every two days. An initial dose of about 0.05 ml can be applied subcutaneously, followed by an increase of 0.01-0.02 ml every two days until a sufficient skin reaction is achieved at the injection site (for example, a delayed reaction of 1 inch to 2 inches of visible redness at the injection site). Once this sufficient immune response is achieved, administration is continued in this manner according to the maintenance dose. The maintenance dose can be adjusted from time to time to achieve an expected visible skin reaction (inflammation) at the injection site. Administration can be carried out for a duration of, for example, at least 2 weeks, 2 months, 6 months, 1, 2, 3, 4 or 5 years or longer.
[0285] In some embodiments, the present invention may include antigen compositions administered to one or more epithelial tissues by non-intestinal routes. For example: administered to the skin by intradermal or subcutaneous injection; administered to pulmonary epithelial cells by inhalation. Therefore, in some embodiments, antigen compositions of the present invention are administered so as to cause an immune response in non-intestinal tissues, such as epithelial tissues. In some embodiments, one or more non-intestinal routes of administration may be combined with one or more other routes of administration, such as intramuscular or intravenous administration.
[0286] In various aspects of the invention, the antigenic composition administered to a patient can be characterized as having an antigenic marker, i.e., a combination of antigens or epitopes that are sufficiently specific so that the antigenic composition is able to elicit an immune response, such as an adaptive immune response, specific to a particular pathogen.
[0287] The amount of active compound (e.g., bacterial species, virus, protozoa or parasite or antigen thereof) in the compositions of the invention may vary according to factors such as the disease state, age, sex and weight of the individual. The dosage regimen may be adjusted to provide the optimal therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate the parenteral composition in dosage unit form for ease of administration and uniformity of dosage.
[0288] In the case of antigen preparations, the compounds of the present invention of immunogenic effective amount can be provided individually or in combination with other compounds. The compound can also be connected to a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity. Antigen composition is a composition comprising a material that causes a desired immune response. Antigen composition can select, activate or expand memory B, T cells, neutrophil granulocytes, monocytes or macrophages of the immune system, for example to reduce or eliminate the symptoms of microbial infection. In some embodiments, the specific pathogenic microorganisms, viruses, viral antigens, bacteria, bacterial antigens or their compositions of the present invention can cause an expected immune response when any other reagent is lacking, and therefore can be regarded as an antigen composition. In some embodiments, the antigen composition may include a suitable carrier, such as an adjuvant, which is a reagent that acts in a non-specific manner to enhance the immune response to a specific antigen or to a group of antigens, so that the amount of antigen in any given dose can be reduced, or the dosage frequency required for producing an expected immune response can be reduced. The bacterial antigen composition may include live bacteria or dead bacteria that can induce an immune response to an antigenic determinant that is usually associated with bacteria. In some embodiments, antigen composition can include as attenuated strain (attenuation), and therefore causes the live bacteria of not too serious infection.In some embodiments, antigen composition can include can induce live, attenuated or dead virus for the immunne response of the antigenic determinant usually associated with virus.
[0289] Antigen compositions containing killed organisms for administration by injection can be prepared as follows. The organisms can be grown in suitable culture media and washed with physiological saline. The organisms are then centrifuged, resuspended in saline solution, and heat-killed. The suspension can be standardized by direct microscopic counting, mixed in the required amount, and stored in a suitable container, and its safety, shelf life, and sterility can be tested in an approved manner. In addition to the organisms and / or their antigens, the killed formulations suitable for use in humans can include phenolic preservatives (e.g., 0.4%) and / or sodium chloride (e.g., 0.9% magnitude). The composition can also include a trace of brain heart infusion (beef), peptone, yeast extract, agar, sheep blood, dextrose, sodium phosphate, and / or other culture medium components.
[0290] In some embodiments, the antigenic composition may be provided as an aerosol for inhalation.
[0291] In general, the compositions of the present invention should be used without producing significant toxicity. Standard techniques can be used, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio of LD50 (the dose that is lethal to 50% of the population) and LD100 (the dose that is lethal to 100% of the population) to determine the toxicity of the compounds of the present invention.
[0292] In some embodiments, the bacterium that is a member of the endogenous flora of the GIT specific region can be used for preparing antigen composition of the present invention. Table 1 each row has been listed many bacterial species, together with the biological region that each species wherein can form a part of the endogenous flora. For example, some species of oligotrophy (Abiotrophia spp.) are members of the endogenous flora of the oral cavity normally.
[0293] Table 1: Normal human bacterial flora (endogenous bacterial pathogens in humans)
[0294]
[0295]
[0296]
[0297]
[0298]
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305]
[0306] Endogenous microbial flora, such as bacteria, enter tissues and cause disease by contact transmission or bacteremia transmission. Under favorable conditions, all endogenous organisms can become pathogenic and local invasion and spread to adjacent tissues and organs by contact transmission. The endogenous bacterial flora of skin, oral cavity and colon is considered to be also suitable for species of bacteremia transmission. Therefore, the bacteria of members of the specific endogenous flora range can cause infection in tissues or organs to which these bacteria can be transmitted. Therefore, one aspect of the present invention relates to the use of endogenous microbial pathogens to treat microbial infections with symptoms localized to the GIT region where endogenous bacteria can be transmitted and cause infection. Each column of Table 2 has listed the scope of endogenous flora. Each row of Table 2 has listed the GIT region where possible microbial infections are located. Therefore, one aspect of the present invention relates to the use of endogenous microbial pathogens to prepare antigenic compositions, or select existing preparations with pathogens, for the treatment of microbial infections in the GIT region where pathogens can be transmitted and cause infection. Thus, in alternative embodiments, symptomatic microbial infections in the areas listed in the first column of Table 2 may be treated with an antigenic composition comprising an antigenic determinant specific for a microbial pathogen that is a member of the endogenous flora of one or more of the endogenous flora ranges listed in the first row of Table 2 and indicated with an X or check mark in the appropriate row.
[0307] Table 2: Tissue / organ pathogenicity of endogenous flora
[0308] Based on the information in the combined Tables 1 and 2, microbial infections manifested in the specific GIT regions set forth in Column 1 of Table 2 can be treated with an antigenic composition comprising an antigenic determinant of the corresponding microbial species of Table 1, such that the column headings in Table 2 are effectively replaced by the bacterial species of Table 1.
[0309] In some embodiments, pathogen that is used for the present invention can be exogenous bacterial pathogen.For example, the biology listed in the table 3 can be used to prepare antigen composition as microbial pathogen, perhaps can select the antigen composition with those pathogens, be used to treat the microbial infection in the GIT region that is listed together with the relevant biology listed in the table 3.In some embodiments, the antigenic determinants of two kinds of endogenous and exogenous bacterial species of target specific tissue or organ can be used in combination.For example, be derived from Clostridium difficile or have specific antigen composition to it and can be used for treating the microbial infection in the colon.
[0310] Table 3: Exogenous bacterial pathogens in humans and their infection sites in the GIT
[0311]
[0312]
[0313]
[0314] In some embodiments, the pathogen used in the present invention may be a viral pathogen. Table 4 provides an exemplary list of viral pathogens along with tissue and organ sites for which each viral species is reported to be a pathogen. Thus, one aspect of the present invention relates to the use of immunogenic compositions specific for the named viruses to treat pathologies associated with heterologous infections in the GIT region identified near the viral name in Table 4.
[0315] Table 4: Human viral pathogens and their infection sites
[0316]
[0317] Cumulative information in Table 1 to 4 provides a broad identification of pathogens that can be used to prepare antigen compositions of the present invention, with identification of pathogenic GIT regions where these organisms are present, and therefore identifies the GIT region where infection is present, which can be treated with antigenic antimicrobial preparations of the present invention. Pathogen can be selected from endogenous pathogens or exogenous pathogens.
[0318] In some embodiments, the pathogen selected for antigen composition of the present invention can be the pathogen of the common causes of acute infection in the residing GIT zone for microbial infection to be treated.Table 5 has identified this type of antibacterial and viral pathogens, and they often cause the GIT zone of infection therein.Therefore, in selected embodiment, the microbial infection that resides in the GIT zone of identification in the table 5 first row, as the IBD associated infection, can be used to comprise the antigen composition treatment of the antigenic determinant of one or more pathogenic organisms listed in the table 5 second row.
[0319] Table 5: Common causes of acute infections (bacterial and viral) in selected GIT regions
[0320]
[0321] The specific organisms that commonly cause infection in a particular GIT region may vary with geographic location. Table 5 is therefore not an exhaustive list of common pathogens in all geographic locations and population groups. It should be understood that a clinical microbiologist skilled in the art can determine the common pathogenic species in a particular geographic region or population group for a particular GIT region based on the present invention.
[0322] Humans are hosts to a wide variety of gastrointestinal parasites, including various protozoa and parasites, which for the purposes of the present invention constitute pathogens of the GIT (Schafer, TW, Skopic, A. Parasites of the small intestine. Curr Gastroenterol Reports 2006; 8:312-20; Jernigan, J., Guerrant, RL, Pearson, RD Parasitic infections of the small intestine. Gut 1994; 35:289-93; Sleisenger & Fordtran's Gastrointestinal and liver disease. 8th edition. 2006; Garcia, LS Diagnostic medical parasitology. 5th edition. 2007). Thus, the compositions of the present invention may include antigenic components of various protozoa, including, for example: Giardia lamblia, Cryptosporidium parvum, Cryptosporidium hominis, hominus, Isospora belli, Sarcocystis species, Coccidian (Cyclospora species), Enterocytozoon bieneusi, Entamoeba histolytica, Entamoeba dispar, Entamoeba coli, Entamoeba hartmanni, Endolimaxnana, Iodamoeba bütschlii, Dientameobafragilis, Blastocystis hominus, Cyclospora cayetanensis, Microsporidia, Trypanosoma cruzi cruzi), Chilomastix mesnili, Pentatrichomonas hominis, and Balantidium coli.Similarly, the compositions of the invention may include antigenic components of various parasites, including, for example: Cestodes (tapeworms), Taenia saginata, Taenia solium, Diphyllobothrium species, Hymenolepis nana, Hymenolepis diminuta, Dipylidium caninum, Nematodes (round worms), Ascaris lumbricoides, Strongyloides stercoralis, Necator americanus, Ancylostoma duodenale, Ancylostoma caninum, Tichuristrichiura, Capillaria philippinarum, philippinensis), Trichostrongylus species, Trichinella species, American nematodes, Anisakis and related species, Angiostrongylus costaricensis, Enterobius vermicularis, Trematodes (flukes), Fasciolopsis buski, Heterophyes species, Echinostoma species, Clonorchis sinensis, Opisthorchis species, Fasciola species, Metagonimus yokogawi, Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma intercalatum, Echinostoma species, and Paragonimus species.
[0323] According to the above, in various aspects, the present invention may involve the use of a formulation to treat a microbial infection, such as a microbial infection of the GIT, or an IBD-related microbial infection, wherein the pathogen is selected from: fermentative amino acid coccus; certain species of Acinetobacter; certain species of Actinomycetes; certain species of Actinomyces; certain species of Aeromonas; forked stick anaerobic bacteria; hydrogen-producing anaerobic cocci; anaerobic lactolyticus; anaerobic cocci of Prevotella; certain species of Atopobium; certain species of Bacillus; Bacteroides faecalis; Bacteroides gibbsii; Bacteroides elsdenii; Bacteroides fragilis; Bacteroides faecium; Bacteroides ovalis; Bacteroides viscerae; Bacteroides thetaiotaomicron; Bacteroides vulgaris; Bifidobacterium adolescentis; Bifidobacterium bifidum; Bifidobacterium breve; Bifidobacterium catenella; Bifidobacterium dentate; Bifidobacterium longum; Bilophila vorticella; Burkholderia cepacia; Butyrivibrio fibrinolyticus; Campylobacter concise; Campylobacter curvifolia; Campylobacter gracilis; Campylobacter jejuni; Campylobacter rectum; Campylobacter showa; Capnocytophaga chrysogenum; Citrobacter freundii; Citrobacter krebsii; Clostridium species; Desulfovibrio inertus; Dysgonomonas species; Eikenella corrodens; Enterobacter aerogenes; Enterobacter cloacae; Enterobacter gorgofycetes; Enterobacter sakazakii; Enterobacter tylosus; Enterococcus species; Escherichia coli; Escherichia fergusonii; Escherichia herschii; Escherichia woundii; Eubacterium species; Finegoldia; Microorganisms Fusobacterium subtilis; Fusobacterium mortis; Fusobacterium navicula; Fusobacterium necroticum; Fusobacterium nucleatum; Fusobacterium rabbis; Fusobacterium variable; Gardnerella vaginalis; Gemini coccus; Streptococcus globosum; Hafnia alvei; Helicobacter spp.; Klebsiella spp.; Lactobacillus acidophilus; Lactobacillus fermentum; Lactobacillus reuteri; Lactobacillus salivarius; Lactobacillus nondecarboxylate; Leminella spp.; Megasphaera elsdenii; Polyacidic mitochondria; Mobiluncus kohnii; Mobiluncus timidus; Millerella wisconsinensis; Morganella morganii; Pantoea agglomerans; Pediococcus spp.; Peptophilus insaccharolyticus; Peptostreptococcus anaerobicus; Peptostreptococcus microsporus; Porphyromonas insaccharolyticus; Proteus mirabilis; Proteus pinnates; Proteus vulgaris; Providencia rettgeri; Providencia stuartii; Pseudomonas aeruginosa; Intestinal Trichomonas; Ruminococcus; Serratia liquefaciens; Serratia marcescens; Serratia odorifera; Streptococcus agalactiae; Streptococcus anginosus; Streptococcus bovis; Streptococcus constellatus; Streptococcus intermedius; Group C+G Streptococci; Vibrio succinidolysinophilus; certain species of Sartonella; Theilonia acuta; certain species of Veillonella; certain species of Aerobacillus; Bacillus anthracis; Bacillus cereus; certain species of other Bacillus; Borrelia recurrentis; certain species of Brucella; Campylobacter coli; Campylobacter fetus; Campylobacter jejuni; Campylobacter salivarius; Clostridium bifermentans; Clostridium botulinum; Clostridium difficile; Clostridium indolici; Clostridium mangenolii;Clostridium perfringens; Clostridium sludge; Clostridium sporogenes; Clostridium subterminale; Edwardsiella tarda; Francisella tularensis; Listeria monocytogenes; Mycobacterium bovis; Mycobacterium tuberculosis; Pediococcus species; Plesiomonas shigelloides; Rickettsia rickettsii; Salmonella species; Shigella boydii; Shigella dysenteriae; Shigella flexneri; Shigella sonnei; other Spirillum species; Streptococcus zooepidemicus; Trophicola whipplei; Vibrio cholerae; Vibrio fluvialis; Vibrio furnisius; Vibrio hominis; Vibrio parahaemolyticus; Yersinia enterocolitica; Yersinia pseudotuberculosis; herpes simplex virus (1 and 2); cytomegalovirus; adenovirus; orthoreovirus; rotavirus; alphavirus; coronavirus; torovirus; human metapneumovirus; vesicular stomatitis virus; Machupovirus; Junin virus; poliovirus; coxsackievirus; echovirus; hepatitis A virus; norovirus and other caliciviruses; astrovirus; picornavirus; and hepatitis E virus.
[0324] In alternative aspects, the invention may relate to treating a microbial infection, such as an infection of the GIT, or an IBD-related infection, with a formulation, wherein the pathogen is selected from the group consisting of small and large intestinal pathogens, for example: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteritidis, Yersinia enterocolitica, Shigella flexneri, adenovirus, astrovirus, calicivirus, norovirus, rotavirus, and cytomegalovirus.
[0325] In selected embodiments, the invention relates to a diagnostic step of assessing a patient's prior exposure to an organism. For example, the diagnostic step may include obtaining a medical history of exposure to a selected pathogen, and / or evaluating a patient's immune response to a selected pathogen. For example, a serological test may be performed to detect antibodies to a selected pathogen in a patient's serum. In connection with this aspect of the invention, an antigenic determinant of a selected pathogen may be selected for use in an immunogenic composition for a selected patient based on a diagnostic indication that the patient has had one or more prior exposures to the pathogen, such as by the presence of antibodies to the antigenic determinant of the pathogen in the patient's serum.
[0326] In other selected embodiments, the present invention relates to a diagnostic step of assessing a patient's immune response to treatment with a selected immunogenic composition. For example, the diagnostic step may include assessing a patient's immune response to the antigenic determinants of the immunogenic composition, such as using a serological test to detect antibodies to those antigenic determinants. In connection with this aspect of the invention, if the assessment indicates that there is a positive immune response to the antigenic determinants of the composition, treatment with the selected immunogenic composition may be continued, and if the assessment indicates that there is not a sufficiently positive immune response to the antigenic determinants of the immunogenic composition, the treatment may be stopped, and an alternative treatment with a different immunogenic composition may be started.
[0327] One aspect of the present invention relates to treating the pathology relevant to pulmonary microbial infection with antigen composition, and the antigen composition comprises the antigenic determinant of the microbial pathogen of the pathogen of the member of the endogenous flora of respiratory system known as pulmonary pathogen, such as pulmonary exogenous pathogen or the member of the endogenous flora of respiratory system.For example, the antigenic determinant of the endogenous bacterial respiratory flora species that most often causes infection (referring to Table 5) in the lung can be used for treating the infection in the lung: Streptococcus pneumoniae, Moraxella catarrhalis, Mycoplasma pneumoniae, Klebsiella pneumoniae, Haemophilus influenzae.Similarly, the common pulmonary viral pathogens from Table 5 can be selected for use in some embodiments.Alternatively, more detailed endogenous pulmonary pathogen list can be selected from Table 1 based on the pathogenicity information provided in Table 2.In other alternative embodiments, the pulmonary viral pathogens listed in Table 4 can be used. And in another alternative embodiment, the pulmonary exogenous bacterial pathogens from Table 3 can be used to formulate the antigenic composition of the present invention, i.e. selected from: Achromobacter spp., Actinomadura spp., Alcaligenes spp., Anaplasma spp., Bacillus anthracis, other Bacillus spp., Pasteurella spp., Bartonella henselae, Bergeyella zoohelcum, Bordetella holmesii, Bordetella parapertussis, Bordetella pertussis, Bordetella burgdorferi, Borrelia relapsingii, Brucella spp., Burkholderia gladiolus, Burkholderia spp. gladioli), Burkholderia mallei, Burkholderia pseudomallei, Campylobacter fetus, Capnoctyophaga canimorsus, Capnoctyophaga cynodegmi, Chlamydia pneumoniae, Chlamydia psittaci, Chromobacter pneumoniae, Chromobacterium violaceum, Chlamydophila psittaci, Chryseobacterium spp.), Corynebacterium pseudotuberculosis, Coxiella burnetii, Francisella tularensis, Gordonia spp., Legionella spp., Leptospira spp., Mycobacterium avium, Mycobacterium kansasii, Mycobacterium tuberculosis, other mycobacterium spp., Nocardia spp., Orientia tsutsugamushi, Pandoraea spp., Pseudomonas aeruginosa, other Pseudomonas spp., Rhodococcus spp., Rickettsia conorii conorii), Rickettsia prowazekii, Rickettsia rickettsii, Rickettsia typhi.
[0328] Infections may also occur in bronchial tissue and thus, in some embodiments, antigenic compositions comprising antigenic determinants of microbial pathogens known to cause bronchial infections may be used to treat patients with infections in bronchial tissue, including, for example, the following common causes of bronchial infections: Mycoplasma pneumoniae, Chlamydophila pneumoniae, Bordetella pertussis, Streptococcus pneumoniae, Haemophilus influenzae, influenza virus, adenovirus, rhinovirus, coronavirus, parainfluenza, respiratory syncytial virus, human metapneumovirus, or coxsackievirus. Infections located in both lung and bronchial tissue may be treated with antigenic compositions comprising antigenic determinants of microbial pathogens known to cause both lung and bronchial infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae are all common lung and bronchial pathogens) or, alternatively, with antigenic compositions comprising antigenic determinants of microbial pathogens known to cause lung infections and antigenic determinants of microbial pathogens known to cause bronchial infections.
[0329] One aspect of the present invention relates to treating the pathology associated with colon microbial infection with an antigenic composition, the antigenic composition comprising antigenic determinants of heterologous microbial pathogens known as colonic pathogens, such as pathogens of members of the endogenous flora of the colon or exogenous colonic pathogens. For example, the antigenic determinants of the following microbial species can be used to treat heterologous infections in the colon: Escherichia coli, Clostridium difficile, Bacteroides fragilis, Bacteroides vulgaris, Bacteroides thetaiotaomicron, Clostridium perfringens, Salmonella enteritidis, Yersinia enterocolitica, Shigella flexneri; Adenovirus, Astrovirus, Calicivirus, Norovirus, Rotavirus or Cytomegalovirus. In selected embodiments, the antigenic determinants of Escherichia coli (the most common bacterial cause of colon infection) can be used alone or in combination with antigenic determinants of other common pathogens of the colon for treating the pathology associated with colon infection, such as the pathology associated with infection caused by heterologous strains of Escherichia coli.
[0330] In alternative aspect, the present invention utilizes microbial pathogens, such as bacterial or viral pathogens, to prepare antigen compositions, wherein the tissue or organ selection microbial species that can cause infection according to known microorganisms. The resident flora of bacteria is the modal bacterial pathogen, which is the cause of the vast majority of bacterial infections in most animals, including humans. The resident flora can, for example, be attached to in the early stage, or in the mucosal damage caused by, for example, blood vessels, trauma, chemical damage, or by the attachment and invasion infection after the damage caused by primary infection.
[0331] For microbial pathogens, toxicity and infection potential are microbial attachment, enzyme production, the combination of the ability to withstand immune products (complement, antibody) and the ability to withstand the microbicidal activity of macrophages and neutrophils. Some bacteria, including endogenous bacteria, can have enough toxicity to cause monomicrobial infection, while others are more effective in synergizing with polymicrobial infections. Generally speaking, it is often impossible to be accurate about the specific effect of a single microorganism in a mixed infection environment. Because in some cases, acute infection can provide better immunostimulation, therefore, in some embodiments, the present invention utilizes microbial species related to acute infection.
[0332] In some embodiments, the antibacterial of endogenous flora member in a specific region can be used for preparing antigen composition of the present invention.Table 6 each row has been listed many bacterial species, together with wherein each species can form the biological region of a part of endogenous flora.For example, some species of oligotrophic bacteria are members of respiratory tract and oral endogenous flora normally.Further and for example, the biology listed in the table 6 can be used as microbial pathogens for preparing antigen composition, or can select the antigen composition with those pathogens, be used for treating heterologous infection, for example be used as the antimicrobial treatment of the heterologous infection in the tissue or organ listed together with the relevant biology listed in the table 6.
[0333] Table 6: Normal human bacterial flora (endogenous bacterial pathogens in humans)
[0334]
[0335]
[0336]
[0337]
[0338]
[0339]
[0340]
[0341]
[0342]
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353] Endogenous microbial flora, such as bacteria, enter tissues and cause disease through contact transmission or bacteremia transmission. Under favorable conditions, all endogenous organisms can become pathogenic and locally invade and spread to adjacent tissues and organs through contact transmission. The endogenous bacterial flora of the skin, oral cavity and colon is considered to be also suitable for species of bacteremia transmission. Therefore, bacteria that are members of a specific endogenous flora range can cause infection in tissues or organs to which these bacteria can be transmitted. Therefore, one aspect of the present invention relates to the use of endogenous microbial pathogens to treat infections in tissues or organs where endogenous bacteria can be transmitted to cause infection. Each column of Table 7 lists 9 ranges of endogenous flora: skin, respiratory system, genitals, GU system, oral cavity, stomach, duodenum / jejunum, ileum and colon. Each row of Table 7 lists organs or tissues where possible microbial infections are located. Therefore, one aspect of the present invention relates to the use of endogenous microbial pathogens to prepare antigenic compositions, or select existing preparations with pathogens for the treatment of heterologous microbial infections in tissues or organs where pathogens can be transmitted to cause infection. Therefore, in alternative embodiments, the infection in the tissue or organ listed in the first row of Table 7 can be treated with the antigen composition comprising the antigenic determinant that microbial pathogens are specific, and the microbial pathogens are members of the endogenous flora of one or more endogenous flora scopes listed in the first row of Table 7 and indicated with X or check mark in appropriate rows.For example, the infection in the prostate can be treated with the antigen composition having a specific antigenic determinant to GU system and / or reproductive system endogenous a kind of microbial pathogens or multiple pathogens.Many bacterial species endogenous in the endogenous flora scope listed in Table 7 are listed together with the corresponding endogenous flora in Table 6.Therefore, one aspect of the present invention relates to the infection in the tissue listed in Table 7 with the antigen composition treatment that comprises the antigenic determinant of bacterial species listed in Table 6, wherein the endogenous flora region associated with the infection site in Table 7 matches the endogenous flora region associated with the bacterial species in Table 6.The example provided in Table 6 and 7 can be used for preparing the antigen composition that is used to treat the infection of heterologous microorganisms, for example as the antimicrobial therapy of the heterologous microorganisms infection in the organ of Table 6 and 7 logos.
[0354] Table 7: Tissue / organ pathogenicity of endogenous flora
[0355]
[0356]
[0357] *Bacteria can enter tissues / organs through: contact line transmission (X) or bacteremia transmission: (√).
[0358] Based on the information in combined Tables 6 and 7, infections located in the tissues or organs set forth in Column 1 of Table 7 can be treated with an antigenic composition comprising an antigenic determinant of a bacterial species corresponding to but heterologous to Table 6, such that the column headings in Table 7 are effectively replaced by the bacterial species of Table 6.
[0359] In some embodiments, the microbial pathogens used for the present invention can be exogenous bacterial pathogens.For example, the organism listed in the table 8 can be used to prepare antigen compositions as microbial pathogens, or can select the antigen compositions with those pathogens, be used to treat the pathology relevant to the heterologous infection in the tissue or organ listed together with the related organisms listed in the table 8.In some embodiments, the antigenic determinants of two kinds of endogenous and exogenous bacterial species of target specific tissues or organs can be used in combination.For example, be derived from Clostridium difficile or have specific antigen compositions to it and can be used to treat the pathology relevant to the heterologous microorganism infection in the colon.
[0360] Table 8: Exogenous bacterial pathogens in humans and their infection sites
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368] In some embodiments, the microbial pathogens used in the present invention may be viral pathogens. Table 9 provides an exemplary list of viral pathogens along with tissues and organ sites for which each viral species is considered a pathogen. Thus, one aspect of the present invention relates to the use of immunogenic compositions specific for the named viruses to treat pathologies associated with infection caused by heterologous microorganisms in organs or tissues identified near the viral names in Table 9. For example, antigenic compositions derived from or specific for vaccinia viruses can be used to treat diseases characterized by infection by heterologous microorganisms in the skin, blood tissue, lymph nodes, brain, spinal cord, eyes, or heart.
[0369] Table 9: Viral human pathogens and their infection sites
[0370]
[0371]
[0372]
[0373]
[0374] The cumulative information in Tables 6 to 9 provides a broad identification of microbial pathogens that can be used to formulate the antigenic compositions of the present invention, and identification of tissues or organs in which these organisms are pathogenic, and thus identifies the correspondence between selected tissues or organs where heterologous organisms infect, and organisms that can be used to produce antigenic preparations for treating said conditions.
[0375] In some embodiments, the microbial pathogen selected for use in the antigen composition of the present invention can be the pathogen of the common cause of acute infection in the tissue or organ of the heterologous infection to be treated therein. Table 10 has identified this type of bacterial and viral pathogens, and they often cause tissue and organ of infection therein. Therefore, in selected embodiments, the infection residing in the tissue identified in the first column of Table 10 can be treated with the antigen composition comprising the antigenic determinants of one or more heterologous pathogenic organisms listed in the second column of Table 10. For example, the infection in the skin can be treated with the antigen composition comprising the antigenic determinants of one or more heterologous organisms: Staphylococcus aureus, A, B, C and G group beta hemolytic streptococci, Corynebacterium diphtheriae, Corynebacterium ulcerans, Pseudomonas aeruginosa, measles, rubella, varicella-zoster, echovirus, coxsackievirus, adenovirus, vaccinia, herpes simplex or parvovirus B19.
[0376] Table 10: Common causes of acute infection (bacterial and viral) per tissue / organ site
[0377]
[0378]
[0379]
[0380]
[0381]
[0382]
[0383] In selected embodiments, specific microbial pathogens are suitable for treating specific pathologies associated with heterologous microbial infections located in tissues or organs in which the organisms are pathogenic, examples of selected embodiments are listed in Table 10. These are exemplary embodiments and are not an exhaustive list of alternative formulations for use in accordance with the present invention.
[0384] In specific tissues or organs, the specific microorganisms that often cause infection can change with geographical location.For example, mycobacterium tuberculosis is the more common lung infection reason and therefore in some geographical locations and population than in other geographical locations and population, although mycobacterium tuberculosis may not be common lung pathogen in some geographical locations and population groups, it may be common lung pathogen in other geographical locations and population groups.Therefore table 10 is not the exhaustive list of all geographical locations and population group common pathogens.Should be appreciated that clinical microbiologists skilled in the art can determine according to the present invention for specific tissues or organ sites, the common pathogen species in specific geographical areas or population groups.For veterinary purposes, certainly there will be common specific pathogens in the selected tissue of selected species, and this also may change with geographical location.
[0385] In selected embodiments, the present invention relates to a diagnostic step of assessing a patient's prior exposure to a microbial pathogen. For example, the diagnostic step may include obtaining a medical history of exposure to a selected pathogen, and / or evaluating a patient's immune response to a selected pathogen. For example, a serological test may be performed to detect antibodies to a selected pathogen in the patient's serum. In connection with this aspect of the invention, an antigenic determinant of a selected microbial pathogen may be selected for use in an immunogenic composition for a selected patient based on a diagnostic indication that the patient has had one or more prior exposures to the pathogen, such as by the presence of antibodies to the antigenic determinant of the pathogen in the patient's serum.
[0386] In other selected embodiments, the present invention relates to a diagnostic step of assessing a patient's immune response to treatment with a selected immunogenic composition. For example, the diagnostic step may include assessing a patient's immune response to the antigenic determinants of the immunogenic composition, such as using a serological test to detect antibodies to those antigenic determinants. In connection with this aspect of the invention, if the assessment indicates that there is a positive immune response to the antigenic determinants of the composition, treatment with the selected immunogenic composition may be continued, and if the assessment indicates that there is not a sufficiently positive immune response to the antigenic determinants of the immunogenic composition, the treatment may be stopped, and an alternative treatment with a different immunogenic composition may be started.
[0387] In selected embodiments, the microbial pathogen selected for use in the antigen composition of the present invention can be a pathogen that is the most common cause of acute infection in the tissue or organ in which the heterologous infection is to be treated. For example, for the treatment of bone infection-related pathology, Staphylococcus aureus will be the bacterial species selected for treating infections caused by heterologous organisms; for the treatment of infections in lung tissue, Streptococcus pneumoniae will be selected for treating infections caused by heterologous organisms; for the treatment of breast infections, Staphylococcus aureus will be selected for treating infections caused by heterologous organisms; for the treatment of kidney or bladder infections, Escherichia coli will be selected for treating infections caused by heterologous organisms; and for the treatment of infections in the colon, Escherichia coli will be the bacterial species selected for treating infections caused by heterologous organisms. It should be understood that clinical microbiologists skilled in the art can determine the most frequent pathogenic species, bacteria or viruses for each specific tissue or organ according to the present invention. In selected embodiments, only the antigenic determinants of the most common pathogens of a specific tissue or organ are used to treat heterologous infections of that tissue or organ. In alternative embodiments, antigenic determinants of the pathogen most common to a particular tissue or organ may be combined with antigenic determinants of other pathogens known to be pathogenic in that particular tissue or organ, preferentially selected from the more common pathogens.
[0388] In some embodiments, the invention provides antigenic composition, wherein relative to any other antigenic determinant in the composition, use the antigenic determinant selected according to the present invention of threshold ratio.For example, can have the antigenic determinant of the species that is derived from pathogenicity (or often pathogenicity, or most often pathogenicity) higher than X% in the antigenic composition, wherein X for example can be 10,30,40,50,60,70,80,90,95 or 100 (or any integer value between 10 and 100).For example, in the antigenic composition, at least X% antigenic determinant can be specific to the microbial pathogen of pathogenicity (or often pathogenicity, or most often pathogenicity) in the patient's specific organ or tissue where heterologous infection is located.Use alternative measures, in the total amount of microbial pathogens in the antigenic composition, at least X% can be selected as the microbial pathogen of pathogenicity (or often pathogenicity or most often pathogenicity) in the patient's specific organ or tissue where heterologous microorganisms are infected. In some embodiments, the antigenic composition may therefore consist essentially of antigenic determinants of one or more microbial pathogens, each of which is pathogenic (or is often pathogenic or is most often pathogenic) in a specific organ or tissue of the patient where the heterologous infection is located.
[0389] In some embodiments, the present invention includes the use of bacterial or viral vaccines or preparations approved for other purposes (e.g., polio vaccine, Haemophilus influenzae vaccine, meningococcal vaccine, pneumococcal vaccine, influenza vaccine, hepatitis B vaccine, hepatitis A vaccine, diphtheria vaccine, tetanus vaccine, pertussis vaccine, measles vaccine, mumps vaccine, rubella vaccine, varicella vaccine, BCG vaccine, cholera vaccine, Japanese encephalitis vaccine, rabies vaccine, typhoid vaccine, yellow fever vaccine, smallpox vaccine, etc.), by consulting Tables 6-10 to select a vaccine containing a pathogen (or an antigenic component of a pathogen) that is pathogenic in the specific organ or assembly of the patient where the heterologous infection is located, for use as a treatment for infection caused by a heterologous microorganism. For example, a pneumococcal vaccine, a whole cell vaccine or a vaccine composed of one or more antigenic components of pneumococcal vaccine (e.g., 23-valent pneumococcal polysaccharide) can be used to treat heterologous infection at any of the following sites, where pneumococcal infection is listed as a common pathogen in Table 10: hilar lymph nodes, bone, meninges, spinal cord, eye / orbit, sinus, thyroid, bronchi, lung, pleura or peritoneum. As another example, a hepatitis B vaccine can be used to treat heterologous infection at any of the following sites, as follows: liver, pancreas or blood infection, where hepatitis B virus is listed as a common pathogen in Table 9.
[0390] In some embodiments, selected compositions and methods are specifically excluded from the scope of the present invention. For example, preparations of specific microbial pathogen antigens are used in the treatment of pathologies associated with infection with that organism. For example, selected embodiments exclude the use of PVF or MRV vaccines to treat lung infections caused by organisms present in those preparations.
[0391] Example 1: Rodent Studies
[0392] Example 1a: Demonstrates the effects of a heat-killed Klebsiella pneumoniae antigenic composition on monocyte / macrophage and dendritic cell populations in mice.
[0393] The following methods and materials were used in this example:
[0394] Mice. C57BL / 6 female mice, 7-8 weeks old, were ordered from Harlan Labs (Livermore, CA) for these studies.
[0395] Antibodies and reagents. The following antibodies were used in this example: anti-IA / IE FITC (MHC class II; M5 / 114.15.2); anti-Gr-1 PE (RB6-8C5); anti-CD11b PerCP-Cy5 (M1 / 70); anti-CD11c APC (N418); anti-CD4 FITC (GK1.5); anti-NK1.1 PE (PK136); anti-CD8a eFluor780 (53-6.7); anti-CD44 APC (IM7). All antibodies were obtained from eBioscience (San Diego, CA). Release enzyme TM and DNase I were obtained from Roche. All culture media were from HyClone (Fisher).
[0396] Treatment with antigenic composition. Heat-killed Klebsiella pneumoniae (KO12 [5.0 OD600 units]) containing phenol was diluted 1 / 10 in PBS containing 0.4% phenol and 100 μl was injected subcutaneously into 4 mice on days 0, 2, 4 and 6. Control mice (n=5) were injected with PBS on days 0, 2, 4 and 6.
[0397] Bronchoalveolar lavage. The 7th day, mice were put to death and bronchoalveolar lavage (BAL) was performed by exposing the trachea and then inserting a 22G catheter connected to a 1ml syringe. 1ml of PBS was injected into the lungs and taken out and placed in a 1.5ml microcentrifuge tube. The lungs were then washed 3 times with 1ml of PBS and fluid was collected. The first washing solution from each mouse and the frozen supernatant were centrifuged at 400xg for cytokine analysis. The last 3ml of lavage solution was centrifuged and cells were collected with cell masses from the first lavage. Cell counts were performed and specific antibodies were used to stain MHC class II, Ly6G / C, CD11b and CD11c. After staining, cells were washed and analyzed on a FACS Calibur flow cytometer.
[0398] Lung digestion. After BAL, the lungs were placed in 5 ml of RPMI containing 417.5 μg / ml Liberase TL (Roche) and 200 μg / ml DNase I (Roche). The lungs were then digested at 37°C for 30 minutes. After digestion, the lungs were forced through a 70um cell strainer to produce a single cell suspension. The cells were then centrifuged, washed, resuspended in FACS buffer (PBS with 2% FCS and 5mM EDTA) and counted. After counting, the cells were stained and analyzed by FACS using the same antibodies as for BAL cells.
[0399] Peritoneal lavage. After BAL, 1 ml of PBS was injected into the peritoneum of the mouse using a 1 ml syringe connected to a 25G needle. The abdomen was massaged for 1 minute and 0.5 ml of PBS was removed from the peritoneum using a 1 ml pipette. The lavage fluid was placed in a 1.5 ml centrifuge tube, centrifuged at 400 x g for 5 minutes, and resuspended in FACS buffer before staining and FACS analysis.
[0400] Spleen and lymph node analysis.After BAL and peritoneal lavage, take out spleen and draining lymph node and put into PBS.Through 70 μ m cell strainer (Fisher) to destroy spleen and use the rubber end of the piston from 1 ml syringe to destroy lymph node.After destruction, centrifugal single cell suspension from spleen and lymph node, wash once with FACS buffer, and be resuspended in FACS buffer, count, dye and FACS analysis afterwards.
[0401] FACS analysis. The cells were stained on ice in a 96-well plate using 50ul of antibody diluted in FACS buffer for 20 minutes. After 20 minutes, 100μl of FACS buffer was added to the wells and the plate was centrifuged at 400xg for 5 minutes. The culture medium was then removed and the cells were washed once more with FACS buffer. After the last wash, the cells were resuspended in 200μl of FACS buffer and data were acquired using a FACS Calibur flow cytometer (BD). A minimum of 20,000 live events were collected for all samples, except for BAL, which collected a minimum of 5,000 events.
[0402] The following results were obtained in this example.
[0403] Normal mice were treated with Klebsiella pneumoniae antigenic composition at day 0, 2, 4 and 6. Mice were killed at day 7 and monocytes and macrophages of bronchoalveolar lavage fluid, lung tissue, peritoneal lavage fluid, lymph nodes and spleen were analyzed for changes. An increase in the number of acute inflammatory blood monocytes / macrophages defined by the high expression of CD11b and Gr-1 (identical to Ly6c) and F4 / 80 in the lymph nodes drained by the Klebsiella pneumoniae antigenic composition injection site was observed (see: Figure 1 A). These acute inflammatory monocytes / macrophages also expressed very high levels of MHC class II molecules, indicating exposure to bacterial antigens. Importantly, treatment of mice with Klebsiella pneumoniae antigenic compositions for one week resulted in a significant increase in the frequency of acute inflammatory monocytes in the bronchoalveolar lavage fluid and lungs (i.e., the targeted organs), but not in the spleen or peritoneum of treated mice, indicating that treatment can induce monocytes to specifically home to the lungs without affecting other organs (see: Figure 1B). Monocytes can differentiate into dendritic cells (DC) in the lung, and consistent with our observation of a significant increase in monocyte recruitment we also observed a significant increase in the frequency of cells displaying markers of mature DC (see: Figure 1 C).
[0404] like Figure 1 As described in , treatment with Klebsiella pneumoniae antigenic composition for 7 days resulted in a significant increase in both acute inflammatory monocytes and dendritic cells in the lungs of mice (compared to treatment with placebo = PBS). Figure 1 As described in, mice were treated with Klebsiella pneumoniae antigenic composition or PBS on days 0, 2, 4 and 6. On day 7, mice were sacrificed and the total number of A) and B) inflammatory monocytes (CD11b+ Gr-1+ cells) and C) dendritic cells (CD11c+ MHC II+ class cells) in the lungs and spleen was determined by flow cytometry. The error bars depicted in A) represent the average of 4-5 mice per group.
[0405] Example 1B. Demonstration of the Effects of Heat-Inactivated Klebsiella Pneumoniae Antigenic Compositions and Heat-Inactivated Escherichia Coli Antigenic Compositions on Monocyte / Macrophage, Dendritic Cell and Effector Cell Populations in Mice
[0406] The following methods and materials were used in this example:
[0407] Mice. C57BL / 6 female mice, 7-8 weeks old, were ordered from Harlan Labs (Livermore, CA) for these studies.
[0408] Antibodies and reagents. The following antibodies were used: anti-IA / IE FITC (MHC class II; M5 / 114.15.2); anti-Gr-1 PE (RB6-8C5); anti-CD11b PerCP-Cy5 (M1 / 70); anti-CD11c APC (N418); anti-CD4 FITC (GK1.5); anti-NK1.1 PE (PK136); anti-CD8a eFluor780 (53-6.7); anti-CD44 APC (IM7). All antibodies were obtained from eBioscience (San Diego, CA). Liberase TM and DNase I were obtained from Roche. All culture media were from HyClone (Fisher).
[0409] Treatment with antigenic composition. Heat-killed Klebsiella pneumoniae (Klebsiella pneumoniae; batch KO12; 5.0 OD600 units) containing phenol was diluted 1 / 10 in PBS containing 0.4% phenol and 100 ul was injected subcutaneously into 5 mice on days 0, 2, 4 and 6. Heat-killed Escherichia coli (batch; 5.0 OD600 units) was diluted 1 / 10 in PBS containing 0.4% phenol and 100 μl was injected subcutaneously into 5 mice on days 0, 2, 4 and 6. Control mice (n=5) were injected with PBS on days 0, 2, 4 and 6.
[0410] Bronchoalveolar lavage. The 7th day, mice were put to death and bronchoalveolar lavage (BAL) was performed by exposing the trachea and then inserting a 22G catheter connected to a 1ml syringe. 1ml of PBS was injected into the lungs and taken out and placed in a 1.5ml microcentrifuge tube. The lungs were then washed 3 times with 1ml of PBS and fluid was collected. The first washing solution from each mouse and the frozen supernatant were centrifuged at 400xg for cytokine analysis. The last 3ml of lavage solution was centrifuged and cells were collected with cell masses from the first lavage. Cell counts were performed and specific antibodies were used to stain MHC class II, Ly6G / C, CD11b and CD11c. After staining, cells were washed and analyzed on a FACS Calibur flow cytometer.
[0411] Lung digestion. After BAL, the lungs were placed in 5 ml of RPMI containing 417.5 μg / ml Liberase TL (Roche) and 200 μg / ml DNase I (Roche). The lungs were then digested at 37°C for 30 minutes. After digestion, the lungs were forced through a 70 μm cell strainer to produce a single cell suspension. The cells were then centrifuged, washed, resuspended in FACS buffer (PBS with 2% FCS and 5 mM EDTA) and counted. After counting, the cells were stained and analyzed by FACS using the same antibodies as for BAL cells.
[0412] Peritoneal lavage. After BAL, 1 ml of PBS was injected into the peritoneum of the mouse using a 1 ml syringe connected to a 25G needle. The abdomen was massaged for 1 minute and 0.5 ml of PBS was removed from the peritoneum using a 1 ml pipette. The lavage fluid was placed in a 1.5 ml centrifuge tube, centrifuged at 400 x g for 5 minutes, and resuspended in FACS buffer before staining and FACS analysis.
[0413] Spleen and lymph node analysis.After BAL and peritoneal lavage, take out spleen and draining lymph node and put into PBS.Through 70 μ m cell strainer (Fisher) to destroy spleen and use the rubber end of the piston from 1 ml syringe to destroy lymph node.After destruction, centrifugal single cell suspension from spleen and lymph node, wash once with FACS buffer, and be resuspended in FACS buffer, count, dye and FACS analysis afterwards.
[0414] FACS analysis. The cells were stained on ice in a 96-well plate using 50 μl of antibody diluted in FACS buffer for 20 minutes. After 20 minutes, 100 μl of FACS buffer was added to the wells and the plate was centrifuged at 400×g for 5 minutes. The culture medium was then removed and the cells were washed once more with FACS buffer. After the last wash, the cells were resuspended in 200 μl of FACS buffer and data were acquired using a FACS Calibur flow cytometer (BD). A minimum of 20,000 live events were collected for all samples, except for BAL, which collected a minimum of 5,000 events.
[0415] The following results were obtained in this example:
[0416] like Figure 2 As described in, mice were treated with Klebsiella pneumoniae antigenic composition, Escherichia coli antigenic composition or PBS on days 0, 2, 4 and 6. On day 7, mice were sacrificed and the total number of inflammatory monocytes (CD11b+Gr-1+ cells) and dendritic cells (CD11c+MHC II+ class cells) in peritoneal lavage fluid, lungs, lymph nodes and spleen were determined by flow cytometry. Fig.18 Error bars in represent standard deviation from 5 mice. *p value < .05 using Student's t-test.
[0417] Figure 2 It is shown that the treatment with Klebsiella pneumoniae antigen composition, rather than Escherichia coli antigen composition, significantly increases the number of monocytes and DCs in the mouse lungs. In contrast to the lungs, Klebsiella pneumoniae does not cause an increase in monocytes in the mouse peritoneum, while Escherichia coli causes an increase in monocytes in the mouse peritoneum. Importantly, only the number of inflammatory monocytes in the spleen of mice treated with Klebsiella pneumoniae or Escherichia coli increases slightly, while DC does not increase, indicating that the effect of the therapy is not universal and in fact specific to a particular organ site. In addition to investigating the effects of treatment on inflammatory monocytes and DCs in the mouse lungs, we also investigated the changes in other leukocytes such as cytotoxic CD8 T cells, CD4 T helper cells, and natural killer (NK) cells.
[0418] Figure 3It is shown that the Klebsiella pneumoniae antigen composition, but not PBS or Escherichia coli antigen composition, leads to a significant increase in the frequency and total number of NK cells, CD4 and CD8 T cells in the lungs of treated mice. This example demonstrates that subcutaneous injection of killed bacterial species that usually cause lung infection can promote the accumulation of leukocytes in the lungs without any inflammation at this site. In addition, it is demonstrated that this effect is specific to the target site and that it is also specific to the bacterial component of the treatment used.
[0419] like Figure 3 As described in, mice were treated with Klebsiella pneumoniae antigenic composition, Escherichia coli antigenic composition or PBS at days 0, 2, 4 and 6. On day 7, mice were sacrificed and the total number of CD4 T cells, CD8 T cells and natural killer (NK) cells were determined by flow cytometry. Error bars represent the standard deviation of the values obtained from 5 mice per group. *p value <.05 using Student's t test.
[0420] Example 1C. Illustrates the effects of heat, radiation, and phenol inactivation on K. pneumoniae antigenic compositions, including leukocyte recruitment to the lungs of mice, and the role of phenol as a preservative.
[0421] The following methods and materials were used in this example:
[0422] Mice. C57BL / 6 female mice, 7-8 weeks old, were ordered from Harlan Labs (Livermore, CA) for these studies.
[0423] Antigenic composition. In this study, heat-killed Klebsiella pneumoniae antigenic composition (KO12) containing phenol, heat-killed Klebsiella pneumoniae antigenic composition (KO25) without phenol, irradiated Klebsiella pneumoniae antigenic composition (KO24) without phenol, and phenol-killed Klebsiella pneumoniae antigenic composition (KO25) without phenol were used. All preparations were 5.0 OD units in saline. For 1 / 10 dilution, 1 ml of bacterial preparation was added to 9 ml of DPBS and mixed immediately, and then mixed again before injection. For 1 / 100 dilution, 0.1 ml of bacterial preparation was added to 9.9 ml of DPBS and mixed immediately, and then mixed again before injection. For the dilution of heat-killed Klebsiella pneumoniae antigenic composition with phenol, the DPBS solution containing 0.4% phenol (w / v) was used as above for dilution. To prepare 0.4% phenol in DPBS, first prepare a 5% phenol solution by adding 0.5 g of solid phenol (Sigma Aldrich, St. Louis, MO) to 10 ml of DPBS (Hyclone, Logan, UT). The solution was filtered through a 0.22 um filter (Millipore, Billerica, MA) and stored at 4° C. Immediately before use, 1 ml of the 5% phenol solution was diluted in 12.5 ml of DPBS and used to prepare the bacterial preparation.
[0424] Treated with antigenic composition. Five mice per group were treated subcutaneously on days 0, 2, 4, and 6 with 0.1 ml of a heat-killed Klebsiella pneumoniae antigenic composition diluted 1 / 10 in PBS or PBS containing 0.4% phenol, 0.1 ml of an irradiated Klebsiella pneumoniae antigenic composition diluted 1 / 10 in PBS, or a phenol-inactivated Klebsiella pneumoniae antigenic composition diluted 1 / 10 in PBS or PBS containing 0.4% phenol. Mice were sacrificed on day 7 and analyzed for leukocyte recruitment to the lungs as in Example 1B.
[0425] The following results were obtained in this example:
[0426] In this example, we used leukocyte recruitment to the lung as a surrogate for efficacy to compare the efficacy of K. pneumoniae antigenic compositions inactivated by various methods. Figure 4Explanation, for both heat-killed and phenol-killed Klebsiella pneumoniae antigen compositions, as measured by cell recruitment, adding phenol (0.4%) as a preservative increases efficacy. In some embodiments, a small amount of phenol (i.e., 0.4% as a preservative) can stabilize components of bacterial cell walls, such as components that are very important in antigen pattern recognition and activation of optimal targeted responses. In comparing 3 preparations containing phenol as a preservative (i.e., heat-killed, phenol-killed and radiation-killed), the irradiated Klebsiella pneumoniae antigen composition causes the maximum recruitment of acute inflammatory monocytes, DC, NK cells and T cells to the lungs, followed by the phenol-killed Klebsiella pneumoniae antigen composition, wherein the heat-killed Klebsiella pneumoniae antigen composition causes minimal cell recruitment.
[0427] like Figure 4 As described in, mice were treated with heat-inactivated (HKWP) or no (HKnp) phenol preservative, phenol-inactivated Klebsiella pneumoniae antigenic composition with (PKWP) or no (PKnp) phenol preservative, or Klebsiella pneumoniae antigenic composition inactivated by radiation with phenol preservative (IRWP) at 0, 2, 4 and 6 days. On the 7th day, mice were sacrificed and the total number of (A) inflammatory monocytes (CD11b+Gr-1+) and DCs (CD11c+Iab+) or (B) CD4 T cells, CD8 T cells and natural killer (NK) cells were determined by flow cytometry. Error bars represent the standard deviation of the values from 5 mice in each group. Using the student's t test, compared with mice treated with IRWP, * p-value < .05.
[0428] Example 2: Site-specific studies
[0429] Focusing on the M1 / M2 phenotype in the in vivo model described herein used together with antigen composition described herein, the following experiment was performed. In brief, 5 mice per group were processed with PBS, Escherichia coli colon antigen composition or Klebsiella pneumoniae antigen composition at day 0, 2, 4 and 6. On the 7th day of the experiment, mice were killed and bronchoalveolar lavage was performed. Lungs and proximal colon were subsequently taken out and enzymatically digested. After digestion, recovered cells were washed and stained with antibodies specific for IA / IE FITC (MHC class II; M5 / 114.15.2); anti-Gr-1 PE (RB6-8C5_; anti-CD11b PerCP-Cy5 (M1 / 70); anti-CD11c APC (N418). All antibodies were obtained from eBioscience (San Diego, CA). Lung cells were counted to determine the total number of cells (colon was not counted because we did not remove equal amounts of colon between samples). After 20 minutes of staining, cells were washed and analyzed by FACS. Figure 5 Each data point shown in represents the frequency of CD11b+Gr-1+ cells in the viable gate of each mouse. Figure 5 As shown, treatment with the Escherichia coli antigenic composition resulted in an increase in the frequency of inflammatory monocytes in the colon of treated mice.
[0430] In addition, and if Figure 6 As shown, when examining monocytes in the lungs based on the experimental methods detailed herein, it was found that while both Escherichia coli and Klebsiella pneumoniae antigenic compositions increased the frequency of monocytes in the lungs of mice, the Klebsiella pneumoniae antigenic composition was more effective when counting the total number. Figure 6 , the leftmost graph shows the frequency of CD11b+Gr-1+ (inflammatory monocytes) in the lungs; the rightmost graph shows the total number of CD11b+Gr-1+ cells in the lungs.
[0431] Example 3: Microbial Prevention in the Lung
[0432] Example 3a: Klebsiella pneumoniae-derived antigen preparation (SSI) protects against S. pneumoniae challenge in the lung.
[0433] This example illustrates that a fully killed Klebsiella pneumoniae SSI formulation administered subcutaneously in mice induces an increase in circulating monocytes and provides protection against a subsequent bacterial challenge with Streptococcus pneumoniae introduced into the nasopharynx. Streptococcus pneumoniae or Pneumococcus is a Gram-positive, alpha-hemolytic, aerobic member of the order Lactobacillales. In contrast, Klebsiella pneumoniae is a Gram-positive, non-motile, encapsulated, lactose-fermenting, facultative anaerobic member of the order Enterobacteriales. These organisms are classified in different isolate classes.
[0434] C57BL / 6 mice were pretreated with placebo or K. pneumoniae preparations subcutaneously every other day for three weeks and then treated with 1x10 9 The mice were challenged with 100 CFU of S. pneumoniae P1547 and monitored for signs of clinical infection for 5 days. On day 5, the mice were sacrificed (moribund mice were sacrificed 5 days earlier) and the bacterial load and immune parameters were evaluated.
[0435] like Figure 7 As illustrated in A, mice treated with the K. pneumoniae preparation were protected from S. pneumoniae infection (5 / 5), whereas mice treated with placebo were only partially protected (3 / 5). In addition, TNF and MCP-1 gene expression in the lungs of resistant mice (treated with SSI and placebo) was higher than that of placebo-treated mice that succumbed to infection. Figure 7 B illustrates the reduced bacterial counts in the nasal cavity, lungs, and spleen after SSI treatment.
[0436] Example 3b: Klebsiella pneumoniae-derived antigen preparation (SSI) protects against Pseudomonas aeruginosa or Streptococcus pneumoniae challenge in the lung.
[0437] Pseudomonas aeruginosa (PA14, 7.8×10 8 CFU / mouse), the mice were pretreated with 30 μL PBS or SSI prepared by killing whole Klebsiella pneumoniae every other day for 3 weeks, and the survival rate was Fig.9A As shown in Figure 9B, among the 6 surviving mice on day 5, 3 / 6 of the PBS-treated group had bacteria in the lungs while only 2 / 10 of the SSI-treated mice had bacteria in the lungs.
[0438] 8-10 week old C57Bl / 6 mice were instilled with Streptococcus pneumoniae (P1542, 4.1×10 6 CFU / mouse), the mice were pretreated with 30 μL PBS or SSI prepared by killing whole Klebsiella pneumoniae every other day for 3 weeks, and the survival rate was Fig.10 shown.
[0439] This example demonstrates that subcutaneously administered SSI formulations of fully killed Klebsiella pneumoniae induce prophylactic antimicrobial activity against infection with Pseudomonas aeruginosa or S. pneumoniae in the lungs in mice. FIG9 illustrates a significant increase in survival in P. aeruginosa challenge, and Fig.10 Demonstrating increased survival during S. pneumoniae challenge.These data demonstrate that an antigenic composition of one pulmonary pathogen mediates effective protection against two heterologous pulmonary pathogens.
[0440] Example 3c: Comparison of Klebsiella pneumoniae-derived antigen preparation (SSI) and Escherichia coli-derived antigen preparation (SSI) in protecting against Streptococcus pneumoniae or Pseudomonas aeruginosa challenge in the lung.
[0441] In this example, Klebsiella pneumoniae SSI (QBKPN) demonstrated statistically superior prophylactic efficacy compared to Escherichia coli SSI (QBECO) in protecting against S. pneumoniae or P. aeruginosa challenge in the lung.
[0442] For the P. aeruginosa model, mice were treated with the indicated SSI (0.03 ml / injection) for 14 days and then inoculated with P. aeruginosa (PA14) by intranasal instillation of 6.0 x 10 8 Three days later, lungs were aseptically removed, homogenized, and bacterial loads were assessed using Pseudomonas selective agar plates. Fig.15 Results are shown (data are CFU / g of lung (mean + / - standard deviation)) demonstrating that K. pneumoniae SSI (QBKPN) exhibited statistically superior protective efficacy compared to E. coli SSI (QBECO) in protecting against P. aeruginosa challenge in the lung.
[0443] For the S. pneumoniae model, mice were treated with the indicated SSI (0.03 ml / injection) for 14 days and then inoculated with S. pneumoniae (PA14) by intranasal instillation of 5.0 x 10 5 Three days later, lungs were aseptically removed, homogenized, and bacterial loads were assessed using Pseudomonas selective agar plates. Fig.16 Results are shown (data are CFU / g of lung (mean + / - standard deviation)) demonstrating that K. pneumoniae SSI (QBKPN) exhibited statistically superior protective efficacy compared to E. coli SSI (QBECO) in protecting against S. pneumoniae challenge in the lung.
[0444] Example 4: Antimicrobial therapy in the GIT
[0445] This example demonstrates heterologous antimicrobial therapy in a mouse model of inflammatory bowel disease using a specific species (NRG 857) of adherent invasive Escherichia coli (AIEC) to induce a chronic IBD-like infection in the colon of the 129e strain of mice with reduced ability to clear AIEC.
[0446] 129e mice were infected with NRG 857 and treated with (1) placebo, (2) a whole-killed cell preparation of Escherichia coli ( Figure 8 or (3) whole-killed cell preparations of Salmonella enterica serovar Enterica, a pathogen that can cause gastrointestinal infections in mice ( Figure 8 The results demonstrate that the whole-kill preparation of E. coli effectively reduced NRG 857 counts in colon tissue (300-fold lower than placebo-treated mice - note that the graph is on a logarithmic scale) and feces of 129e mice. In addition, the S. enterica preparation also exhibited some antimicrobial activity against heterologous AIEC infection.
[0447] According to one aspect of the invention, macrophage deficiency or insufficiency, resulting in a reduced ability to clear bacterial infection and necrotic debris, may be a potential trigger for some pathologies associated with microbial infection. This has been postulated to be the case, for example, in Crohn's disease. Various aspects of the invention therefore relate to the induction of organ-specific macrophage recruitment and activation, leading to the clearance of bacterial infection.
[0448] Example 5: Antimicrobial Prophylaxis in the Peritoneal Cavity
[0449] In a first aspect, this example demonstrates that the full-kill E. coli SSI formulation is effective in protecting against Salmonella enterica. Fig.11 As demonstrated in , SSI-treated mice had significantly fewer bacteria in the spleen than saline-treated mice (p<0.0001), and SSI-treated mice had less peak weight loss than saline-treated mice (p<0.02).
[0450] In an alternative aspect, this example demonstrates that two alternative whole-kill E. coli SSI formulations (QBECO and QBECP) made from different strains of E. coli are effective in protecting against S. enterica challenge in a mouse model, with levels of protection comparing favorably to a previously administered antigenic S. enterica formulation (QBSEN). In this example, mice were pretreated by cutaneous injection of the alternative formulations, QBECO, QBECP (SSI from urinary E. coli), or QBSEN (each given every other day for 3 weeks), and then infected with S. enterica. Survival was improved for all treatments, as illustrated in FIG12A , with QBECP providing comparable benefit to QBSEN. Mice were sacrificed, and colony counts in the spleen were quantified and as shown in FIG12A . Fig.12 As illustrated in B, the colony counts were found to be lower in all treatment groups. Fig.12 As illustrated in C, body weight loss was found to be lower in all treatment groups.
[0451] In further illustration of targeted and optimized intraperitoneal prophylaxis, mice were treated with alternative SSIs, QBKPN and QBECO, or vehicle; then Salmonella enterica (S. typhimurium) was instilled IP at 1.0 x 10 6 Three days later, spleens were aseptically removed, homogenized and the bacterial load was assessed on Hektoen enteric agar plates. Fig.19 It was demonstrated that both QBECO and QBKPN were protective as measured by bacterial load in the spleen, with counts in QBECO-treated mice significantly lower than those in QBKPN-treated mice (data are CFU / ml (mean + / - standard deviation).
[0452] Example 6: Antimicrobial Prevention in Skin
[0453] This example illustrates targeted heterologous antimicrobial therapy in a mouse model of skin infection, demonstrating the improved efficacy of antigen preparations derived from microbial pathogens of the target tissue. Mice were treated with selected antigen preparations of the invention (0.03 ml / injection) for 14 days and then infected with Pseudomonas aeruginosa (PA14) by intradermal injection of 6.5 x 10 5 Three days later, the skin was aseptically excised, homogenized and the bacterial load assessed using Pseudomonas selective agar plates. Fig.13 This suggests that QBSAU (S. aureus -derived SSI) protects against P. aeruginosa challenge in the skin, with a significant reduction in bacterial counts after QBSAU compared to QBKPN (which is not a skin pathogen in the murine model). Fig.14Repeated iterations of the aforementioned procedure reproduced the results as shown (n=8 mice / group).
[0454] Example 7: Antimicrobial prevention in aged mice in an aging model
[0455] This example illustrates targeted heterologous antimicrobial therapy in an aged mouse model of lung infection, showing that Klebsiella pneumoniae SSI (QBKPN) protects against S. pneumoniae challenge in the lungs of aged mice. Fig.17 showed a survival benefit in aged mice, Fig.17 B, Comparison of young mice, Fig.17 A, more significant. Fig.18 Definitive data are presented showing that QBKPN reduces weight loss in aged mice following challenge with S. pneumoniae and that this benefit is greater in aged mice compared to young mice.
[0456] Example 8: Antiviral Prevention in the Lung
[0457] In this example, mice were injected with QBKPN or QBECO SSI or vehicle for 14 days according to the protocol presented in other examples. The mice were then challenged intranasally with murine herpes virus 68 (MHV68), a virus genetically modified to drive a luciferase reporter gene. MHV68 is a model viral pathogen for studying lung infection. Three days after the challenge, mice were injected with 300 micrograms of luciferin; 10 minutes later, the mice were sacrificed, the lungs were excised, and imaged with a Xenogen IVIS imager. Luminescence in the lungs is an indicator of active viral infection and replication.
[0458] Pretreatment of mice with QBKPN SSI significantly reduced the luminescent signal in the lungs of mice, providing evidence of antiviral prevention in the lungs using a targeted antigenic bacterial formulation. The same significant results were not observed for QBECO.
[0459] Other Implementations
[0460] Although various embodiments of the present invention are disclosed herein, many changes and modifications can be made within the scope of the present invention according to the common knowledge of those skilled in the art. Such modifications include substitutions of known equivalents to any aspect of the present invention, so as to achieve the same results in substantially the same manner. In some embodiments, the present invention excludes steps involving medical or surgical treatments. Numerical ranges include numbers that limit the ranges. In this specification, the word "comprising" is used as an open term, substantially equivalent to the phrase "including but not limited to", and the word "comprising" has a corresponding meaning. The citation of references herein should not be construed as admitting that such references are prior art of the present invention. All publications are incorporated herein by reference, as if specifically and individually indicating that each individual publication is incorporated herein by reference and as if fully set forth herein. Substantially as described above and with reference to the examples and drawings, the present invention includes all embodiments and variations.
Claims
1. The invention relates to a method for preparing a medicine for treating or preventing a pulmonary infection caused by herpesvirus in a human patient by using an antigen preparation having a specific antigenic determinant to Klebsiella pneumonia, wherein the antigenic determinant having a specific Klebsiella pneumonia comprises cells of fully killed or attenuated Klebsiella pneumonia.
2. The use according to claim 1, wherein the medicament is formulated for subcutaneous use.
3. The use according to claim 1, wherein the patient is immunosuppressed or immunocompromised.
4. The use according to claim 1, wherein the patient is an elderly patient.
5. The use according to claim 1, wherein the patient is a pediatric patient.
6. The use according to claim 1, wherein the pulmonary infection is a nosocomial infection.
7. Use of an antigenic preparation comprising an antigenic determinant specific for Staphylococcus aureus, wherein the antigenic determinant specific for Staphylococcus aureus comprises fully killed or attenuated cells of Staphylococcus aureus, in the preparation of a medicament for treating or preventing skin infections caused by Pseudomonas aeruginosa in human patients.
